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ABSTRACT 
Chandler L. Walker 
TARGETING ACUTE PHOSPHATASE PTEN INHIBITION AND 
INVESTIGATION OF A NOVEL COMBINATION TREATMENT WITH 
SCHWANN CELL TRANSPLANTATION TO PROMOTE  
SPINAL CORD INJURY REPAIR IN RATS 
Human traumatic spinal cord injuries (SCI) are primarily incomplete contusion or 
compression injuries at the cervical spinal level, causing immediate local tissue 
damage and a range of potential functional deficits. Secondary damage 
exacerbates initial mechanical trauma and contributes to function loss through 
delayed cell death mechanisms such as apoptosis and autophagy. As such, 
understanding the dynamics of cervical SCI and related intracellular signaling 
and death mechanisms is essential.   
 Through behavior, Western blot, and histological analyses, alterations in 
phosphatase and tensin homolog (PTEN)/phosphatidylinositol-3-kinase (PI3K) 
signaling and the neuroprotective, functional, and mechanistic effects of 
administering the protein tyrosine phosphatase (PTP) inhibitor, potassium 
bisperoxo (picolinato) vanadium ([bpV[pic]) were analyzed following cervical 
spinal cord injury in rats. Furthermore, these studies investigated the combination 
of subacute Schwann cell transplantation with acute bpV(pic) treatment to 
identify any potential additive or synergistic benefits. Although spinal SC 
transplantation is well-studied, its use in combination with other therapies is 
necessary to complement its known protective and growth promoting 
characteristics.  
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 The results showed 400 μg/kg/day bpV(pic) promoted significant tissue 
sparing, lesion reduction, and recovery of forelimb function post-SCI. To further 
clarify the mechanism of action of bpV(pic) on spinal neurons, we treated injured 
spinal neurons in vitro with 100 nM bpV(pic) and confirmed its neurprotection and 
action through inhibition of PTEN and promotion of PI3K/Akt/mammalian target of 
rapamycin (mTOR) signaling. Following bpV(pic) treatment and green fluorescent 
protein (GFP)-SC transplantation, similar results in neuroprotective benefits were 
observed. GFP-SCs alone exhibited less robust effects in this regard, but 
promoted significant ingrowth of axons, as well as vasculature, over 10 weeks 
post-transplantation. All treatments showed similar effects in forelimb function 
recovery, although the bpV and combination treatments were the only to show 
statistical significance over non-treated injury. In the following chapters, the 
research presented contributes further understanding of cellular responses 
following cervical hemi-contusion SCI, and the beneficial effects of bpV(pic) and 
SC transplantation therapies alone and in combination. In conclusion, this work 
provides a thorough overview of pathology and cell- and signal-specific 
mechanisms of survival and repair in a clinically relevant rodent SCI model.  
           
          
         
       Xiao-Ming Xu, Ph.D., Chair  
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CHAPTER 1 
 
INTRODUCTION 
 
Background 
Nearly 2 million Americans experience traumatic spinal cord (SCI) and brain 
injuries (TBI) each year (Loane and Faden, 2010, NSCISC, 2011), though 
unfortunately, few treatments are currently available. Investigating cell-specific 
responses, including signal pathways and associated proteins, is important for 
understanding spinal cord and brain pathology and neuroprotection, which could 
enhance therapeutic development. Two widely studied pathways involved in 
cellular responses in both normal and pathological conditions within the CNS are 
the phosphatidylinositol-3-kinase (PI3K)/Akt and mitogen-activated protein kinase 
(MAPK) pathways. These cascades are widely known for their roles in promoting 
survival, growth and proliferation (Chang and Karin, 2001, Cantley, 2002); 
however, their influence is not always beneficial following CNS injury. Much 
research has focused on protection of spared nervous tissue from progressive 
biochemical and inflammatory damage, and regeneration of damaged axons 
following primary mechanical trauma, both with limited success. Such trouble 
likely involves the complexities of these cellular responses following injury.   
 Unlike the peripheral nervous system (PNS), the CNS lacks inherent 
regenerative ability following injury (Schwab and Bartholdi, 1996). Contributing to 
this inhibition are myelin related proteins (Cadelli and Schwab, 1991), including 
myelin associated glycoprotein (MAG) (McKerracher et al., 1994), Nogo-A 
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(GrandPré et al., 2000), and oligodendrocyte myelin glycoprotein (Omgp) (Wang 
et al., 2002). Astroglial-associated inhibitory molecules, including chondroitin 
sulfate proteoglycans (CSPGs), contribute to the extracellular matrix within the 
inhibitory glial scar (Dow et al., 1993). These examples highlight just a few of the 
obstacles in treating CNS injury. Recent research, however, has shown 
remarkable advances in manipulating such barriers, even demonstrating the 
ability to promote CNS axonal regeneration (Park et al., 2008, Liu et al., 2010c). 
Extensive literature currently exists on the variation and influence of intracellular 
signaling on neuroprotection, regeneration, and functional recovery following SCI 
and TBI, and tools are now available which hold the potential for promoting these 
benefits. The following section highlights the progression of pathology, signaling 
through the PTEN/PI3K pathway, and how it may be modulated to improve 
neuroprotection and recovery following CNS injury. These topics are the 
emphasis of this body of work, with a focus on targeting cellular signaling, as well 
as to present a novel combined two-phase therapy combining small molecule 
PTEN inhibitor bpV(pic) and subacute Schwann cell transplantation for improving 
the anatomical and neurological outcome following traumatic cervical hemi-
contusion SCI in rats. 
 
Pathological progression following CNS injury 
After traumatic CNS injury, damage proceeds by two mechanisms: the primary 
mechanical injury, and a subsequent multi-factorial secondary injury. The initial 
physical tissue disruption includes axonal stretching and myelin damage, local 
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cellular destruction and necrosis, and vascular disruption, resulting in infiltration 
of inflammatory and foreign molecules and cells into the typically secluded 
parenchyma of the CNS (Tator and Fehlings, 1991, Casella et al., 2006). 
Currently, the involvement and interaction of cellular signaling pathways 
mediating destructive responses after traumatic CNS injury is unclear. Each cell 
type has a unique mechanism of reacting to injury or insult, ranging from 
neuronal functional disruption and degradation to glial growth, proliferation, and 
migration. As the interaction between the various cells and structures within the 
CNS is essential to the health and function of each and the organism as a whole, 
attempting a single systemic or even local therapy proves insufficient for 
complete neuroprotection. Though two different cell types may share similar 
signaling pathways, the activation, and downstream signaling within and between 
these pathways may be vastly different. As such, targeting the inhibition of a 
potentially detrimental signaling step in neurons may have contradictory or 
undesirable effects on other neural cell types. Nonetheless, limiting the 
expansion of cell death and tissue damage are primary goals for acute treatment 
following SCI and TBI and other CNS injuries. 
 Part of the contribution to cell death following CNS trauma develops from 
ischemic events resulting from the dynamic vascular response that occurs near 
the site of injury following trauma. Cerebrovascular hypoxia/ischemia, 
characteristic of stroke, leads to an anatomical and physiological outcome similar 
to traumatic injuries. Following all these disruptions of normal CNS function, a 
core, or epicenter develops, in which all cells rapidly die due to extensive 
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localized physical disruption or dysfunction of normal cellular activities. 
Surrounding the core is a penumbra of damaged, but surviving cells that can die 
as secondary injury spreads. Without treatments to prevent this spread of tissue 
damage, the core and penumbra of the insult expand radially, occupying a 
greater extent of CNS tissue, and potentially leading to more extensive functional 
abnormalities. Therefore, understanding and treating such injuries and disease 
during the acute phase (within 1 week following injury) with the goal of stemming 
this expansion is a prime goal of experimental and clinical research. Due to the 
importance and urgency of advancing our knowledge and progress in this area, 
this review aims to highlight cellular response including cell death and survival, 
and the mechanisms that may be potential targets for improved prognosis in SCI, 
TBI, and stroke. 
 
Necrosis 
Upon injury to the CNS, significant white matter area damage occurs and the full 
extent of local gray matter is destroyed within 24 hours (Ek et al., 2010). This 
rapid death of local neurons and glial cells at the injury epicenter occurs through 
necrosis and spreads outward from the epicenter over time (Hausmann et al., 
2002). Necrotic cells enlarge through permeability of the cell membrane and 
swelling, and eventually rupture and contribute to the inflammatory response in 
the injury area. Furthermore, extensive release and cellular reactivity to a variety 
of inflammatory-related cytokines and chemokines contribute to progressive 
tissue damage following trauma (Helmy et al., 2011). 
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 The spread of necrosis coincides with a spread of inflammatory cytokines 
such as tumor necrosis factor alpha (TNFα) and interleukin-6β (IL-6β) (Donnelly 
and Popovich, 2008) and infiltration of neutrophils and other leukocytes from the 
damaged vasculature (Milligan and Watkins, 2009). The chronic anatomical 
result of a contusive CNS injury is a system of cavities and fluid-filled cysts 
sealed by extensive glial scar formation (Tator, 1995).  
 
Apoptosis 
Though necrosis is an early cell death mechanism instigated by injury, delayed 
programmed cell death, including apoptosis and macroautophagy also contribute 
to cell loss and tissue pathology. Unlike necrosis, cells induced to undergo 
apoptosis shrink, fragment into smaller membrane-bound structures, and are 
removed through phagocytosis. Neurons respond poorly to mitochondrial 
dysfunction, as mitochondria produce adenosine triphosphate (ATP), help reduce 
reactive oxygen species (ROS), and are involved in regulating the quantity of 
calcium within the cell. Mitochondrial disruption, through outer membrane 
disruption or other insult, dysregulates some or all of these processes, which in 
turn diminishes neuron health. Additionally, an important mitochondria-related 
process involved in programmed neuronal cell death is the release of cytochrome 
c from damaged mitochondria. 
 Cytochrome c released from the damaged mitochondrial inter-membrane 
space interacts with apoptotic protease-activating factor 1 (APAF1) in the cytosol, 
resulting in the formation of the apoptosome. Apoptosomes are responsible for 
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activating caspases, including the well-known catalytic enzyme caspase 3, that 
are responsible for promoting apoptotic cell death (Pasinelli et al., 1998, Tait and 
Green, 2010). Physical or secondary neuronal injury can lead to mitochondrial 
instability, resulting in loss of neurons and other local cells post-injury. 
Disruptions in normal mitochondrial function have been linked to many 
neurodegenerative conditions, including ischemic brain injury (Sas et al., 2007). 
 Recent evidence suggests that the phosphatase and tensin homolog 
(PTEN) induced kinase-1 (PINK-1) is critical for mitochondrial activity and 
protection, as well as PI3K/Akt signal-mediated inhibition of downstream factors 
that promote cell death following CNS injuries or diseases (Shan et al., 2009, 
Akundi et al., 2012). Perhaps as part of a feedback mechanism, evidence 
suggests that Akt may directly interfere with PINK-1 expression and that PTEN 
enhances its expression (Unoki and Nakamura, 2001). It is widely known that 
activity of the mammalian target of rapamycin (mTOR) is a major inhibitor of the 
progression of apoptosis, and stability of mitochondrial function may result from 
PINK-1-induced upregulation of Akt activity and its involvement in the activation 
of mTOR (Akundi et al., 2012).   
 
Autophagy 
Another process considered by many as a separate form of programmed cell 
death, called autophagy, or Type II cell death (Baehrecke, 2005, Levine and 
Yuan, 2005), is also inhibited by active mTOR, though the interplay between 
apoptosis and autophagy is complex and hinders interpretation of analysis 
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(Shang et al., 2010). In addition, biological processes involving autophagy have 
been shown to also occur through mTOR-independent mechanisms (Sarkar et 
al., 2007, Sarkar et al., 2009), underscoring the complexity of identifying specific 
cell signaling effects on survival and death. Autophagy is a normal physiological 
cellular process by which cells recycle aged organelles and proteins. Though 
autophagy is quite complex and not fully understood, it is apparent that basal 
function prevents intracellular accumulation of debris and generation of nutrients 
from intracellular degradation under starvation conditions (Mizushima and 
Komatsu, 2011). Three types of autophagy have been classified: 1) 
microautophagy, during which a cell intakes extracellular material through 
invaginations of the cell membrane, 2) chaperone-mediated autophagy, which 
requires heat shock proteins for proper lysosomal delivery and degradation of 
damaged or irregular proteins, and 3) macroautophagy, during which the cell 
digests its own internal organelles or proteins for nutrients during times of stress 
(Klionsky et al., 2005, Pereira et al., 2012). Macroautophagy is the most fully 
characterized, and most commonly assessed following injury and disease. 
Therefore, this process is often referred to simply as autophagy, as is done here. 
Despite the known benefits of autophagy under stressful conditions, dysregulated 
autophagy is suggested to be a detriment to cell health and survival, and neurons 
are especially susceptible to dysfunction of autophagic processes (Mizushima et 
al., 2008). 
 Enhanced neuronal autophagy is suggested to contribute to cell death in 
some CNS disease or injury models, including SCI (Wang et al., 2008, Wen et 
 
 
8 
 
al., 2008, Kanno et al., 2009, Kanno et al., 2011). As autophagosome 
convergence with lysosomes to form autolysosomes, which is important in 
normal functioning of intracellular degradation (Chen and Klionsky, 2011), 
deregulation of lysosomal cathepsins B and D expression has been shown to 
occur following autophagy-inducing nutrient stress in vitro (Shibata et al., 1998, 
Uchiyama, 2001). Such evidence suggests disruption of processes downstream 
of autophagosome formation, blocking normal degradation and causing 
accumulation of waste-filled autophagosomes, promotes autophagy-induced 
neurodegeneration in contrast to an upregulation of autophagy and 
autophagosome production. As such, the matter of whether injury increases 
autophagy, or autophagy exacerbates injury is still debated. Nonetheless, 
autophagic activity or dysfunction caused by, or contributing to, pathology to CNS 
tissue may increase to a detrimental level, eventually proceeding to delayed cell 
death.  
 As a major part of this process in neurons, dynamic intracellular vesicle 
formation occurs, resulting in construction of the double-membrane 
autophagosome that transport of material from the neuron soma along extended 
processes, and back to the cell body (Xie and Klionsky, 2007, Yang et al., 2008, 
Yang et al., 2011). Resulting from its consistent location within the isolation and 
autophagosome membrane, lipidated microtubule associated protein light chain 3 
(LC3 II) is a widely accepted marker of autophagosomes (Kabeya et al., 2000) 
and are monitored for changes in autophagosome formation and clearance. LC3 
II-positive punctate aggregations of autophagosomes post-SCI have been 
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observed surrounding the injury site within one to three days following thoracic 
contusive SCI (Kanno et al., 2011). TUNEL-positive cells co-localize with Beclin-
1 and LC3-positive cells, indicating autophagosome aggregation precedes 
apoptosis (Kanno et al., 2009, Kanno et al., 2011). We showed that LC3 II-
positive autophagosomes increased in neurons following SCI, and treatment that 
upregulated neuroprotection, function, and Akt and mTOR activity reversed this 
accumulation and reduced LC3 II protein levels (Walker et al., 2012) (Chapter 2). 
A recent study confirmed that autophagosome and ubiquitinated protein 
accumulation occurs in the pathology of SCI, and was reversible through 
neuroprotective activation of the PI3K/Akt/mTOR pathway (Zhang et al., 2013). In 
light of these and our own findings, reduction of autophagy is a promising 
proposition for reducing neural damage following SCI. 
 
PTEN and PI3K/Akt/mTOR signaling 
PI3K signaling is often triggered by extracellular growth factor activation of a 
receptor tyrosine kinase (RTK) or G-protein coupled receptor (GPCR) (Engelman 
et al., 2006) (Fig. 1). Once active, PI3K can phosphorylate phosphatidylinositol-
4,5-phosphate (PIP2) to form phosphatidylinositol-3,4,5-phosphate (PIP3) 
(Engelman et al., 2006). PIP3, a multipurpose secondary messenger, promotes 
activation of the survival kinase Akt (also known as PKB), and its membrane 
localization through activity of 3-phosphoinositide dependent protein kinases 
(PDK) (Alessi et al., 1997). Thus, PIP3 production is essential for PI3K-mediated 
pro-survival signaling through Akt and its effectors. Antagonizing PI3K in PIP2 
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conversion, however, is the phosphatase and tensin homologue deleted on 
chromosome ten, better known as PTEN. Encoded by the pten gene mapped to 
chromosome 10q23, the 55 kD PTEN protein is a dual-function protein tyrosine 
phosphatase that can dephosphorylate both proteins and lipids (Agrawal and 
Fehlings, 1997). Its enzymatic active site, however, has more affinity for the 
latter, especially PIP3 (Lee et al., 1999). The physiologic function of PTEN is 
highly important for processes including cellular proliferation and neuronal growth 
regulation (Dahia, 2000, Kwon et al., 2001). In addition, downregulating PTEN’s 
function or expression promotes axon regeneration and neuroprotection following 
CNS trauma (Park et al., 2008 (Zhang et al., 2007a, Park et al., 2008, Liu et al., 
2010c, Walker et al., 2012) (Fig. 1).  
  PTEN is highly expressed in adult CNS neurons (Cai et al., 2009, Liu et 
al., 2010c), and neuroprotective effects of its inhibition are usually attributed to 
disinhibition of PI3K and downstream signaling through Akt (Zhang et al., 2007a, 
Sury et al., 2011, Walker et al., 2012) and the mammalian target of rapamycin 
(mTOR) (Shi et al., 2009, Zhong and Bowen, 2011). It is well known that mTOR 
inhibits the progression of apoptosis and autophagic cell death (Baehrecke, 
2005, Levine and Yuan, 2005). Activity of mTOR is also linked to axonal 
regeneration following PTEN deletion (Park et al., 2008, Liu et al., 2010c, Sun et 
al., 2011). The understanding of the signaling steps between PTEN and mTOR 
involved in these events are not quite clear, though Akt activity is potentially 
involved based on its known effects and documented response to injury.    
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Figure 1. PTEN reduces PI3K/Akt signaling benefits on cell survival and 
regeneration. PI3K can be stimulated through RTK or GPCR-mediated 
signaling, promoting Akt inhibition of several apoptosis-associated proteins such 
as Bad and FOXO1, and promotion of pro-survival mediators such as mTOR. 
PTEN antagonizes PI3K, and the resulting reduction in downstream Akt and 
mTOR signaling promotes programmed cell death i.e. apoptosis and autophagy. 
PI3K = Phosphatidylinositol 3-Kinase; PTEN = Phosphatase and Tensin 
Homolog; mTOR = mammalian Target of Rapamycin; BAD = Bcl-2-associated 
death promoter; FOXO1 = Forkhead box protein O1; LC3 II = Microtubule-
associated protein light chain 3 II. 
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Akt phosphorylation decreases within the lesion area following SCI (Yu et 
al., 2005, Walker et al., 2012), while increasing in neurons through a PI3K-
dependent mechanism within the surrounding injury penumbra (Yu et al., 2005, 
Endo et al., 2006, Howitt et al., 2012). Akt phosphorylation at serine 473 peaks 8 
hours post-injury within this perilesional tissue (Yune et al., 2008), and 
diminishes through 24 and 48 hours following trauma (Yune et al., 2008, Walker 
et al., 2012). Similarly, phosphorylation at this site decreases rapidly within the 
injury epicenter following TBI, while transiently peaking at 4 hours post-injury in 
the penumbra and co-localizing with its downstream effectors phosphorylated 
Bad and GSK-3β (Noshita et al., 2001). By 24 hours post-TBI, apoptotic co-
labeling with phospho-Akt is not observed (Noshita et al., 2001), further 
associating Akt activation with cell survival following CNS injury. 
Delayed phosphorylation of ribosomal protein S6 at serines 235/236, 
commonly used markers for mTOR activity, is observed 24 hours post-SCI 
(Walker et al., 2012). Further study could uncover a similar downstream mTOR 
activity pattern following TBI. mTOR, also known by the name FRAP (FKBP and 
rapamycin-associated protein), is a large serine/threonine kinase (289 kD) 
responsible for detecting energy or nutrient variations within the cell, and is highly 
important in regulating key cellular functions in response to the energy or stress 
status of the cell (Proud, 2004). mTOR is activated upon phosphorylation at 
serine 2448, and functional interactions with other proteins forms two distinct 
enzymatic complexes, mTORC1 and mTORC2. mTORC1, the rapamycin-
sensitive complex, can be activated indirectly through Akt via phosphorylation of 
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the tuberous sclerosis complex protein 2 (TSC2) (Inoki et al., 2002), which 
prevents mTOR inhibition (Inoki et al., 2002, Jaeschke et al., 2002, Tee et al., 
2002, Manning and Cantley, 2007). 
Primary effectors of mTOR are ribosomal protein p70S6 kinase (p70S6K) 
and 4E binding protein-1 (4E-BP1) (Proud, 2002). Phosphorylation of p70S6K 
stimulates its phosphorylation of ribosomal protein S6, initiating a variety of 
translation-associated activities. Phosphorylation of 4E-BP1 by mTOR promotes 
translation, as well. Some of the most exciting aspects of mTOR’s activation 
have been observed following PTEN inhibition or genetic deletion (Park et al., 
2008, Liu et al., 2010c, Walker et al., 2012, Zhong et al., 2012). A recent report 
suggested that exercise upregulates ribosomal protein S6 activity in intermediate 
grey matter interneurons at 10 and 31 days post-SCI (Liu et al., 2010b), posing 
an interesting question as to whether extensive behavioral testing or training 
activities in SCI and TBI research affect plasticity and neural tissue survival 
through mTOR-associated signaling. 
Increased phospho-Akt in neurons of the injury penumbra (Yu et al., 2005, 
Endo et al., 2006, Howitt et al., 2012) suggests the natural upregulation of this 
pathway may represent an acute endogenous protective response to insult 
(Noshita et al., 2001), especially if followed by a progression of mTOR activation. 
Though this explanation is quite plausible, a better grasp of the temporal 
progression of intracellular pro-survival PI3K/Akt/mTOR signaling within 
penumbral neurons and glia is necessary to effectively identify specific signaling 
targets and therapeutic time windows for promoting neuroprotection and repair 
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following CNS injury. Nevertheless, enough evidence exists suggesting that 
activation of Akt/mTOR, through PTEN inhibition or other means, is likely 
neuroprotective and growth-promoting following injury to the CNS. 
 
Tools for studying PI3K-related signaling in neural degeneration and repair 
Variation in cellular signal transduction complicates investigation of the 
mechanisms of protection and pathology following CNS injury. The use of 
transgenic animals has allowed for more accurate and reliable assessments in 
such studies. Knocking-out specific signaling proteins affords discrete 
assessment of their role in cellular signaling effects. However, pharmacological 
approaches to experimental and clinical treatment are often more practical and 
accessible than genetic manipulation, even though such knock-out investigations 
are critical to highlight potential targets for pharmacological therapeutics. Table 1 
highlights some of the most commonly used chemical inhibitors, their targets, 
and functions for assessing the roles of particular steps of these pathways and 
for experimental assessment of their benefits through modulation in animal 
models of CNS injury and disease. 
A large body of literature currently exists describing many processes and 
treatments that may act through stimulating PI3K/Akt/mTOR axis signaling in 
mediating neuroprotection. In general, many therapies may incite neuroprotective 
signaling through interaction and activation of extra- and intracellular domains of 
receptor tyrosine kinases (RTKs). We have shown that GDNF exerts beneficial 
effects through interaction with GFRα1 and its partner RTK, cRet, and potentially 
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through neural cell adhesion molecule (NCAM) interaction on neurons (Zhang et 
al., 2009). GDNF, however, is known to promote neurite outgrowth in vitro via Erk 
1/2, and not PTEN/PI3K signaling (Koelsch et al., 2010). In vivo however, Liu et 
al. (2010b) have shown that viral-mediated conditional deletion of PTEN in 
cortical neurons promotes enhancement in axon sprouting and regrowth in the 
spinal cord, with upregulated mTOR activity being a likely key intermediary in 
promoting such benefits. Previous work has also demonstrated this phenomenon 
following similar methods of PTEN deletion in an optic nerve injury animal model 
(Park et al., 2008). As such, PI3K pathway signaling can promote axonal 
regeneration depending on the stimulus and the conditions of the neurons under 
study.  
 
Inhibition of PTEN by bisperoxovanadium 
Techniques that involve prevention of specific gene or protein expression provide 
new possibilities for intracellular upregulation of pro-survival signaling which can 
have beneficial effects that occur without extracellular stimulation by an trophic 
factor or ligand. However, deletion of an enzyme may have unintended effects on 
other aspects of cellular function. Pharmacological enzymatic disruption of 
signaling molecules like PTEN provides a much more convenient and less 
extreme method of assessing an enzymes’ activity. For example, 
bisperoxovanadium compounds, also known as bpVs, specifically inhibit PTEN 
signaling, and have been used for promotion of neuroprotection in many CNS 
disease and injury models including Parkinson’s disease, meningitis, stroke, and 
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SCI (Yang et al., 2007, Zhang et al., 2007a, Nakashima et al., 2008, Sury et al., 
2011, Walker et al., 2012, Mao et al., 2013). 
There are several members of the bpV family of compounds including 
bpV(pic), bpV(OHpic) and bpV(phen), all of which have high affinity and potency 
for inhibition of PTEN (Schmid et al., 2004). In neuroprotection studies using bpV 
compounds (Zhang et al., 2007, Sury et al., 2011, Liu et al., 2010a, Nakashima 
et al., 2008, Walker et al., 2012), potentially detrimental systemic effects were not 
observed or reported, however, more investigation is necessary to further verify if 
bpV has undesired off-target effects that may need consideration. Also, support 
for bpV as a CNS injury therapy requires further investigation for treatment of 
other injuries including TBI. Nonetheless, current evidence suggests that small 
molecule inhibition of PTEN lipid phosphatase function appears to be an 
effective, easily controlled, and relatively safe means of reducing the extent of 
tissue damage and enhancing resulting functional recovery. To investigate 
signaling protein effects, or to alter cell signaling in ways similar to bpV, a wide 
variety of chemical inhibitors are commercially available. Table 1 lists several 
commonly used PI3K/Akt/mTOR pathway signaling and related inhibitors. 
 
PI3K/Akt/mTOR, autophagy, and apoptosis inhibitors 
PI3K inhibitors include LY294002 and also wortmannin (Arcaro and Wymann, 
1993, Vlahos et al., 1994). These are often used as potential therapeutics in 
cancer biology, due to the common upregulation of PI3K and Akt signaling 
observed in tumorigenic cells. However, they are also useful in determining PI3K 
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or downstream pathway effects in different neurological conditions both in vitro 
and in vivo. Due to PI3K’s involvement in many cellular processes including Akt 
activation and signaling the range of applications for use of these compounds is 
wide. Important potential uses include investigation of acute effects of PI3K/Akt 
deactivation or activation following CNS trauma and long term anatomical and 
functional therapeutic benefits or deficits. Akt has many inhibitors, the most 
commonly reported being Akt inhibitor IV, which inhibits ATP binding of an 
enzyme upstream of Akt yet downstream of PI3K (Kau et al., 2003), resulting in 
reduced Akt activity in tissue and cell samples. Again since Akt activation is 
tightly controlled by PI3K activity, PI3K inhibition also results in reduced Akt 
activity.   
Rapamycin has long been known for its antibiotic function, and has been 
used as a therapeutic agent to elucidate mTOR influence on neuronal fate post-
injury. One recent study suggests rapamycin can promote autophagy and cell 
survival through mTOR inhibition after SCI (Sekiguchi et al., 2012) and stroke 
(Chauhan et al., 2011, Yan et al., 2011), while others suggest rapamycin-
mediated autophagy promotes neurodegeneration following CNS injury 
(Grishchuk et al., 2011).  
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Table 1. PTEN/PI3K pathway and related inhibitors, their targets and actions. 
PI3K pathway 
inhibitor 
Target Action Reference 
Bisperoxovanadium 
(bpV) 
PTEN 
Inhibits PTEN phosphatase 
activity; Upregulates PI3K/Akt 
signaling 
Schmidt et al., (2004). FEBS 
Lett, 566(1-3):35-8. 
LY294002 
PI3 
Kinase 
Blocks PI3K activity; Reduces 
phosphorylation of Akt at 
serine 473 
Vlahos, C. (1994). J. Biol. Chem, 
269:5241-5248. 
Wortmannin 
PI3 
Kinase 
Blocks PI3K activity; Reduces 
phosphorylation of Akt at 
serine 473 
Arcaro, A. and Wymann, M.P. 
(1993). Biochem. J, 296:297-
301. 
Akt Inhibitor IV Akt 
ATP-competitive inhibitor of a 
kinase upstream of Akt but 
downstream of PI3K 
Wang, G., et al., (2006). Proc. 
Natl. Acad. Sci. U.S.A, 103: 
4640-4645. 
Rapamycin mTOR C1 
Inhibits mTOR's ability to 
phosphorylate p70S6 Kinase 
or 4E binding Protein I 
Kunz, J. et al. (1993). Cell, 
73:585-596; Brown, E. J. et al. 
(1994). Nature, 369:756-758. 
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These discrepancies are debatable, as described earlier, and may be 
injury type-dependent. Nonetheless, rapamycin has proven to be a useful tool in 
examining mTOR signaling both in vitro and in vivo. 3-methyladenine (3-MA) 
(Seglen and Gordon, 1982) is now considered a commonly associated 
autophagy inhibitor, and thus can be used in experiments to verify if progression 
of autophagy is pathologic or beneficial following injury, as well as used in 
conjunction with other pathway inhibitors, e.g. caspase inhibitor Ac-DEVD-CMK, 
to establish mechanisms of action within cells in response to injury, disease, or 
treatment. 
 
Schwann cell transplantation for SCI 
One of the most studied treatments for SCI is Schwann cell (SC) transplantation. 
This therapy has been investigated extensively due to the benefits these cells 
promote once engrafted into the injured spinal cord. Named after German 
anatomist, Theodore Schwann (1810-1882), SCs are the myelinating cells of the 
peripheral nerve and main contributors to the repair mechanism following nerve 
damage. SCs derive from the neural crest during development, and mature from 
SC progenitors to myelinating or non-myelinating SCs through molecular control 
of axons and a variety of specific gene expression and trophic interactions (Fig. 
2) (Mirsky and Jessen, 1996). To develop effective therapies for SCI, treatments 
should target multiple excitatory, inflammatory, and oxidative biochemical 
processes that occur within minutes and can persist chronically in the 
traumatically injured cord. Despite these obstacles, Schwann cells (SCs) have a 
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long history as a potential therapeutic for the treatment of SCI. For even longer, 
spinal cord and brain injuries were considered inoperable and unable to 
regenerate following damage. Regeneration studies, beginning as early as the 
beginning of the 20th century with the work of Ramon y Cajal (Ramon y Cajal, 
1928), and reinvigorated several decades later (David and Aguayo, 1981, Bray et 
al., 1987), showed that spinal axons regenerated into grafted peripheral nerve, 
demonstrating the importance of environment for instigating a regenerative 
response from damaged axons.  
Multiple methods exist to isolate, purify, and expand both rodent and 
human SCs in culture (Wood, 1976, Brockes et al., 1979, Morrissey et al., 1991, 
Casella et al., 1996). Once millions of SCs could be generated in vitro, 
approaches to SC transplantation were developed for laceration and channel 
transplantation studies, as well as in more clinically relevant contusive and 
compression SCI models. In contusive SCI transplantation studies, SCs have 
been shown to survive most effectively when delayed to 7 to 10 days post-SCI 
instead of directly into the inhospitable setting that develops within the injury area 
soon after trauma (Martin et al., 1996, Hill et al., 2006). Delaying implantation of 
the cells avoids not only the cytotoxic environment of the acute injury epicenter, 
but also allows for the development of cystic cavities in which to inject the cells 
into. Even still, SCs have been demonstrated to dramatically die off soon after 
transplantation, with the greatest loss within the first 24 hrs (Hill et al., 2006, Hill 
et al., 2007). It is interesting that endogenous SCs invade the cord from the PNS, 
crossing the glia limitans and weathering the harsh environment of the lesion 
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area following SCI (Blakemore, 1975, Raine, 1976, Beattie et al., 1997, Hill et al., 
2006, Hill et al., 2007). Though migrated host SCs have been shown to promote 
some axon growth and myelination (Oudega and Xu, 2006), they too suffer cell 
loss (Hill et al., 2006, Hill et al., 2007) and do not sufficiently contribute to 
functional recovery. Furthermore, SCs fail to migrate and regenerated axons 
cannot extend into the caudal host tissue due to glial scar formation and 
inhibitory extracellular matrix and myelin-associated molecules. Overcoming 
these obstacles is essential for making functional connections for effective 
sensorimotor and autonomic recovery.  
In light of these issues, it is likely that SCs alone will not be enough to cure 
SCI and fully repair CNS damage. Combination therapies with SC transplantation 
are gaining ground as the next wave in experimental SCI research; nevertheless, 
foundational studies over the past several decades are not without merit, and 
provide history of the biology and breadth of SC transplantation research for 
potential treatment of SCI. 
 
SC biology and functions 
During development, Schwann cell precursors derive from neural crest cells 
(Dupin et al., 1990), eventually developing into immature Schwann cells. A 
variety of environmental chemical cues help direct the fate of SCs during 
development (Fig. 2). The direction of SC survival and progression toward a 
mature phenotype is driven by β-neuregulin-1 (NrG1) (Dong et al., 1995). 
Stimulation of ErbB 2/3 receptor isoforms on the SC by axonal NrG1 type III sets 
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in motion appropriate SC myelination of interacting axons (Garratt et al., 2000, 
Nave and Salzer, 2006). 
The process of axon myelination in the PNS by mature SCs occurs 
approximately at the time of birth in rats (Jessen and Mirsky, 2005). Unlike CNS 
oligodendrocytes, SCs have a “one-to-one” relationship with axons in that any 
individual SC interacts and myelinates only one axon. SCs generally myelinate 
axons of large diameter, while axons smaller in size are organized into Remak 
bundles by non-myelinating SCs. To accommodate myelination once in contact 
with an axon, promyelinating SCs alter their gene and protein expression 
patterns including upregulation of Krox20, and downregulating SOX2 and Jun 
expression (Jessen and Mirsky, 2005, Le et al., 2005, Parkinson et al., 2008). 
Micro-RNA (miRNA) production by the enzyme Dicer is involved in regulation of 
Krox20 mRNA expression, as well as myelination-related protein expression 
including myelin associated glycoprotein (MAG) and PMP22 (Pereira et al., 
2010). Activation of Akt, which is suggested to promote SC survival, proliferation 
and myelination (Campana et al., 1999, Maurel and Salzer, 2000), is reduced by 
defects in Dicer activity in SCs (Pereira et al., 2010). 
Though the interaction between an individual SC and an axon is one-to-
one, many SCs are necessary to effectively myelinate a given peripheral axon 
and SCs line the length of an axon with each spirally ensheathing a segment in 
myelin. The exposed axonal gaps between SCs are called “nodes of Ranvier” 
(Salzer, 2002) (Fig. 2) at which the axon is uncovered and has low resistance to 
signal transduction. Myelin impedes ion transfer between the axon and 
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extracellular environment, and these nodes allow for rapid depolarization and 
unidirectional saltatory transduction of action potentials along the axon. Signals 
traveling in this manner are much faster than those sent along non-myelinated 
axons, making the SC and myelination indispensable for rapid communication 
between neurons and their targets in the PNS.   
 
The role of SCs in repair of damaged axons 
Along with their role in myelination, SCs produce numerous trophic factors and 
regulators of cellular activity. These include glial cell line-derived neurotrophic 
factor (GDNF) (Springer et al., 1994), brain-derived neurotrophic factor (BDNF) 
(Acheson et al., 1991, Meyer et al., 1992), and neurotrophin-3 (NT-3) 
(Offenhauser et al., 1995). Following trauma to peripheral nerves, severed axons 
undergo numerous physiologic changes over time. The distal end of the broken 
axon breaks down through a process known as Wallerian degeneration (Waller, 
1850) and the proximal end, attached the body of the neuron, will also die back 
initially followed by a period of regrowth. At the proximal end, SCs go through 
many cellular and functional alterations including de-differentiation, involvement 
in debris removal, and trophic stimulation of axon regeneration. During this 
period, SCs maintain residence within the surrounding basal lamina forming 
conduits known as bands of Bungner (Bunge, 1994). When retracted axons 
begin to regrow, they do so through bands of Bungner with the trophic and 
structural support of the surrounding SCs and basal lamina. 
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Figure 2. Development and differentiation of Schwann cells. Schwann cells 
derived from the neural crest progress toward a myelinating or non-myelinating 
phenotype depending on the presence and size of interacting axons, as well as 
trophic or other environmental cues. At each stage of development, Schwann 
cells and their precursors express specific markers that aid in the verification of 
the developmental status of the Schwann cell lineage. Dhh = Desert hedgehog; 
ErbB2/3 = SC Nrg receptors; GFAP = Glial fibrillary acidic protein; GGF = Glial 
growth factor; MBP = Myelin basic protein; NGFR(p75); Nerve growth factor 
receptor(p75); Nrg1 Type III= Neuregulin 1 Type III; O4 = SC glycolipid antigen; 
PLP = Myelin proteolipid protein; P0 = Myelin protein zero; S100 = neural crest 
glial protein; Sox10 = SRY-related HMG-box 10.  
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SCs and tissue repair following SCI 
In addition to the PNS, it has long been known that SCs can promote CNS axon 
regeneration (Gilmore, 1971, Blakemore, 1975). The peripheral nervous system 
(PNS) environment is favorable for long distance CNS axon regeneration 
(Richardson et al., 1980, David and Aguayo, 1981, Bray et al., 1987). At the time, 
SCs were considered to be the primary factor contributing to axonal regeneration 
and remyelination within the nerve graft (Salame and Dum, 1985). From 
peripheral nerves, SCs can be isolated and expanded in culture using a variety of 
methods (Brockes et al., 1979, Porter et al., 1986, Morrissey et al., 1991, Casella 
et al., 1996). The use of mitogenic agents supported production of the large 
numbers of SCs required for transplantation (Porter et al., 1986), and since, 
purified SCs have been widely used as an important transplantation strategy for 
experimental and clinical treatment of SCI.  
 
Limitations and methods of improving SC transplantation for SCI 
In spite of the many advantages of SC transplantation, there are certain 
limitations that must be overcome to further the potential for SCs as a viable 
therapeutic for treating SCI. First, the primarily astrocytic glial scar that forms 
around the injury site proves a formidable barrier for SC migration and interaction 
with host tissue. Many studies have demonstrated the lack of interaction between 
engrafted SCs and the glial border of the lesion. This has also been shown in 
vitro through SC and astrocyte confrontation assays (Lakatos et al., 2000, Zhang 
et al., 2009). If SCs can migrate into the caudal host tissue, this could extend the 
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growth promoting properties of the SC graft to allow regenerating axons to make 
functional connections beyond the lesion.  
 Another major limitation of SC transplantation, axons may grow into the 
lesion and SC graft, but fail to exit into the caudal host tissue (Oudega and Xu, 
2006). The glial scar not only prohibits SCs but also axons from extending across 
the lesion to intact host tissue, effectively reducing any functional advantage of 
SC-mediated axon regeneration. Lastly, SCs exhibit poor survival once 
transplanted into the contused spinal cord. Labelled SCs have been tracked 
following transplantation at various time points post-injury and even when 
transplanted at the optimal period for their survival (7-10d post-SCI) the vast 
majority die within the first week following SCI (Hill et al., 2006, Hill et al., 2007). 
To reap the benefits that SC transplantation can offer, promoting their survival is 
key to overcoming any other limitation of this therapy in treating SCI. 
 Fortunately, great effort has been exerted to surmount these obstacles. 
Compared to peripheral nerve grafts, advantages of using purified SCs includes 
the potential for transfection to over-express growth- and survival- promoting 
factors that enhance SC survival and axon regeneration within the host tissue 
following transplantation. Moreover, combination with tissue engineering 
materials adds scaffolding to enhance SCs ability to fill and bridge lesion gaps 
and cavities. Neurotrophic factor GDNF has proven beneficial for axonal growth 
into normal and lentiviral-transfected SC-seeded guidance channels (Iannotti et 
al., 2004, Deng et al., 2011, Deng et al., 2013). Providing a growth-promoting 
pathway caudal to the lesion with a gradient of such factors could enhance 
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axonal extension into host tissue for making functional connections with caudal 
neurons (Fig. 3). To allow for their exit from the graft, degradation of the glial scar 
is important and much work has focused on this area of study.  
 The most studied method of glial scar component degradation has been 
through application of the bacterial enzyme Chrondroitinase ABC. This enzyme 
targets chondroitin sulfate proteoglycans (CSPGs), an inhibitory component of 
the glial scar. Administration of this enzyme in transection SCI models has 
promoted propriospinal, as well as supraspinal axonal growth of the lesion and 
into the caudal host tissue (Chau et al., 2004, Vavrek et al., 2007). Growth 
factors such as GDNF, neurotrophin-3 (NT-3) and BDNF, delivered through 
transplanted genetically-modified SCs and otherwise, have been shown to 
enhance SC survival and minimize the inhibitory effect of astrocytes in the scar to 
promote a more permissive environment for SC migration and axon growth into 
host tissue (Menei et al., 1998, Girard et al., 2005, Zhang et al., 2007b, Deng et 
al., 2011, Deng et al., 2013). Figure 3 illustrates these primary challenges and 
potential solutions to overcome them for progressing SC transplantation 
research. 
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Figure 3. Pathology and experimental challenges following SCI. Upon injury, 
axons are severed, and rostral axon stumps retract while distal segments 
progressively undergo Wallerian degeneration. A glial scar forms including 
inhibitory chondroitin sulfate proteoglycans (CSPGs), preventing grafted SCs 
from migrating, and axons extending into host tissue. Such challenges are 
illustrated and labeled above. SC transplantation-mediated axon regrowth 
includes the following strategies: Genetic modification of SCs to express 
neurotrophins or growth factors, break down the glial scar with Chondroitinase to 
allow axons and SCs to exit into the caudal host tissue, and combination 
therapies with other glial or neural precursor cells, or bioengineered materials, to 
enhance SC benefits on neuroprotection, repair and functional recovery.  
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Summary 
As research into the mechanisms of cell death and tissue degeneration following 
CNS injury continues, more information will be obtained which will aid in the 
development of effective, and specific therapies for preventing, or even 
reversing, the progression of pathology commonly observed following such 
injuries. Understanding the important roles and intricate internetwork 
communication and activity of intracellular pathways, is an important direction for 
making this progress. Current evidence, as described here, suggests that work 
towards understanding PI3K/Akt signaling and other complex signaling cascades 
is not only promising, but may be critical for achieving the goal of improved 
neurological outcome after brain and spinal cord diseases and injuries. In 
combining therapies such as PTEN inhibition by bpV and SC transplantation, the 
mechanistic details of the effects of both therapies on the injured become 
exponentially complicated; nonetheless, combining other treatments with SC 
transplantation is a necessity and from a therapeutic perspective, the end result 
of recovery may be more important than the means of achieving it. 
 The following chapters describe work toward elucidating changes in 
PTEN/PI3K/Akt signaling in the injured spinal cord, the investigation of small-
molecule PTEN inhibitor, bpV, in an effort to reduce spread of secondary tissue 
damage, and a novel combination treatment involving acute delivery of bpV 
followed by subacute SC transplantation to better improve neuroprotection and 
functional recovery in a clinically-relevant hemicontusive cervical SCI model in 
rats. 
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CHAPTER 2 
AIM 1 
 
CHARACTERIZATION OF PTEN/PI3K EXPRESSION AND SIGNALING,  
AND ASSESSMENT OF THE EFFECTS OF PTEN INHIBITOR 
BISPEROXOVANADIUM ON NEUROPROTECTION AND RECOVERY OF THE 
INJURED RAT FORELIMB FOLLOWING SCI 
 
Hypotheses: 1) PTEN activity or expression changes in mediating cell death 
through down-regulation of Akt survival signaling, and 2) that modulating PTEN 
activity with acute bpV administration may promote neuroprotection and 
functional recovery, at least partly, through upregulation of PI3K/Akt activity and 
downregulation of delayed cell death processes following SCI. 
 
Introduction 
Following rapid trauma-induced necrosis at the injury epicenter, apoptosis and 
macroautophagy spread out into the lesion penumbra (Rami and Kogel, 2008), 
contributing to secondary cell death following SCI (Kanno et al., 2009, Kanno et 
al., 2011). These processes are regulated, at least in part, by 
phosphotidylinositol-3-kinase (PI3K)/Akt signaling, with downstream mammalian 
target of rapamycin (mTOR) protein complexes involved in promoting cell 
survival and growth. After CNS trauma, however, many questions remain 
concerning the influence of this signaling pathway, and the cell-specific outcomes 
such activation imparts in response to the insult. Following SCI, Akt 
phosphorylation decreases at and around the injury epicenter, while a PI3K-
mediated upregulation occurs in neurons peripheral to the injury core (Yu et al., 
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2005). This phenomenon is also observed following focal ischemic brain injury, 
and is considered an endogenous neuroprotective response of surrounding 
neurons (Noshita et al., 2001).   
Under normal conditions, downstream effectors in this pathway such as 
mTOR are relatively inactive in spinal cord neurons (Xu et al., 2010). PTEN 
however, is highly expressed in adult CNS neurons (Cai et al., 2009, Liu et al., 
2010c), and negatively regulates this pathway, countering its over-activity, which 
is important for cell cycle regulation, cellular turnover, and cell motility (Dahia, 
2000). Nonetheless, the loss of PTEN or its function is beneficial following CNS 
injury and disease, promoting axonal regrowth following SCI (Liu et al., 2010a), 
reducing motor neuron atrophy (Ning et al., 2010), and enhancing neural survival 
(Zhang et al., 2007a, Shi et al., 2011). Such evidence suggests a potential 
alteration in PTEN expression or activity following SCI.   
Small-molecule protein-tyrosine-phosphatase (PTP) inhibitors, 
bisperoxovanadium (bpV) compounds, are known to promote neuroprotection 
following thoracic SCI (Nakashima et al., 2008), and Parkinsonian 
neurodegeneration (Yang et al., 2007), though no specific cellular signaling 
mechanism was investigated in these reports. bpV compounds specifically and 
potently inhibit PTEN activity in vitro (Schmid et al., 2004), and administration in 
vivo promotes neuroprotection in various CNS injury models through activation of 
the PI3K/Akt pathway (Song et al., 2010, Shi et al., 2011, Sury et al., 2011). Akt 
activity also negatively influences retrograde axonal degradation through 
inhibition of macroautophagy following axotomy (Cheng et al., 2011) a result 
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potentially promoted through inhibition of PTEN. Thus, targeting PTEN may be 
part of the mechanism of bpV-mediated neuroprotection observed following 
spinal trauma.    
Pharmacological therapies for SCI are urgently needed as such 
treatments are minimally invasive and can be rapidly administered. To test our 
hypotheses, histological and protein analysis were utilized, as well as application 
of a novel forelimb functional assessment to investigate acute PTEN/PI3K/Akt 
and mTOR signaling changes and the ability of potassium bisperoxo (picolinato) 
vanadium (bpV[pic]) modulate PI3K/Akt signaling for mediating neuroprotection 
and functional recovery. To our knowledge, these findings are the first to link 
bpV-mediated neuroprotection to PI3K/Akt/mTOR signaling following SCI.   
 
Materials and Methods 
 
Animals and surgical procedures 
Adult female Sprague-Dawley rats (200-250 g, Harlan) (n = 40) were housed in 
controlled conditions with a 12:12 light:dark schedule, and access to food and 
water ad libitum. Prior to surgery, the animals were anaesthetized with ketamine 
(87 mg/kg)/xylazine (12 mg/kg, IP), and either a laminectomy only, or unilateral 
cervical SCI was performed as modified from Gensel et al. (2006). Briefly, a 
customized vertebral stabilizer was set to support the 5th cervical vertebrae and a 
partial unilateral laminectomy was performed to expose the right side of the 
spinal cord at the same level. With dura intact, the NYU MASCIS Impactor 
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(Gruner, 1992) (2.5 mm tip, 10g weight, 12.5 mm height) was used to inflict a 
moderate unilateral injury (Gensel et al., 2006). Sham animals were excluded 
from injury.   
Following surgery, animals received an injection of 3 mL 0.9% saline 
subcutaneously for hydration and were placed in temperature controlled housing 
overnight for monitoring recovery. All surgical and animal handling procedures 
were performed as approved under the Guide for the Care and Use of Laboratory 
Animals (National Research Council) and the Guidelines of the Indiana University 
School of Medicine Institutional Animal Care and Use Committee. 
 
Drug Treatment 
Groups were randomly designated for treatment with bpV(pic) (Enzo Life 
Sciences), with dosing modified from Zhang et al., (Zhang et al., 2007a) or 
vehicle. After surgery and/or injury, animals received an immediate 
intraperitoneal (IP) injection of either saline or bpV(pic). Animals received a 
second dose of vehicle or bpV(pic) 2 hrs post-injury, and twice daily for 1 or 7 
days thereafter. The treatment group received daily injections of 400 μg/kg 
bpV(pic), while a second group received 0.9% sterile saline (vehicle) injection as 
a treatment control. A third group served as a surgical control group (sham) also 
injected with vehicle according the prescribed dosing schedule.   
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Western Blotting 
Protein analysis followed procedures described previously (Xu et al., 1998a, Yan 
et al., 1999, Yan et al., 2003), with modification. Briefly, a 10 mm spinal cord 
segment containing the injury epicenter (5 mm rostral and caudal to the 
epicenter) was removed for protein extraction 24 hours following SCI. The tissue 
was quickly homogenized in RIPA lysis and extraction buffer (25 mM Tris-HCl 
[pH 7.6], 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) + 0.5 
M ethylenediaminetetraacetic acid (EDTA) and 1 % Halt protease inhibitors (100 
mM AEBSF•HCl, 80 µM Aprotinin, 5 mM Bestatin, 1.5 mM E-64, 2 mM 
Leupeptin, 1 mM Pepstatin A) (ThermoPierce) using a Dounce homogenizer (20x 
up and down) and left on ice for 30 min. After this time, the samples were 
centrifuged for 10 min at 10,000 RPM. After centrifugation, the supernatant, 
which represented the primary tissue lysate was removed from each sample and 
placed in new Eppendorf tubes and centrifuged again for 10 min at 10,000 RPM. 
This step removed any remaining cellular debris and membrane leaving total 
tissue lysate. Protein concentrations were determined and standardized using 
the Bradford method (Bradford, 1976). 
 Equal protein concentrations from each sample was loaded onto 8-10% 
polyacrylamide gels, separated by SDS-PAGE, and transferred to a 
polyvinylidene difluoride (PVDF) membrane by electrophoresis. The membranes 
were immunoblotted with the following primary antibodies: monoclonal mouse-
anti PTEN (1:200); monoclonal mouse anti-ribosomal protein S6 (1:200) (Santa 
Cruz Biotechnologies); polyclonal rabbit anti-phospho Akt (ser 473) (1:1,000), a 
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marker used for assessing PI3K activation, monoclonal mouse anti-pan Akt 
(1:1,500); polyclonal rabbit anti-phospho ribosomal protein S6 (ser 235/236) 
(1:400) (Cell Signaling, Inc.) an indicator of mTOR activity; polyclonal rabbit anti-
LC3B (1:100, Abgent), to assess autophagy activity; monoclonal mouse anti-β-
tubulin (1:1000, Sigma-Aldrich) as a loading control. Membranes were incubated 
with a secondary goat anti-rabbit or anti-mouse fluorescent secondary antibody, 
fluorescing at either 680nm or 800nm wavelength (1:10,000; Rockford) and 
visualized with the LiCor Odyssey system and software (Version 1.2) per the 
manufacturer's instructions. Quantification of detected bands was performed by 
densitometry using ImageJ software (NIH). 
 
Histological Assessments 
Six weeks post-injury, tissue was collected and processed as previously 
published (Liu et al., 2006). In brief, a 1 cm segment of cervical cord including the 
injury epicenter (5 mm rostral and caudal to the epicenter) was dissected and 
sectioned longitudinally in the horizontal plane or transversely at 20 μm thickness 
on Superfrost Plus slides (Fisher Scientific) using a cryostat (Leica). Tissue was 
stained using cresyl violet acetate stain with eosin counterstaining. Lesion and 
cavity volume were calculated using Neurolucida software (MicroBrightfield, Inc.). 
Two sections per mm along the length of the cord were used for lesion volume 
measurement and calculation, spanning from tissue first showing identifiable 
lesion, to the last demonstrating such morphology. These same methods, 
equipment, and software were used to construct a 3-dimensional representation 
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of vehicle- and bpV-treated animal spinal cord tissue. Additionally, the same 
sections and staining used for assessing lesion, cavity, and spared tissue volume 
were used to quantify the number of motorneurons throughout the specified 
spinal cord distance illustrated. To define a standard anatomical area for 
counting motorneurons, a horizontal line was drawn from one side of the 
transverse section to the other passing through the central canal. All clearly 
identifiable ipsilateral ventral horn motorneurons ventral to this line, exhibiting 
dark, evenly distributed cresyl violet staining, were manually quantified using 
ImageJ software. 
 
Vascular Quantification 
Six weeks post-injury, spinal tissue sections 2 mm rostral and caudal, as well as 
from the epicenter of the lesion, were utilized for vascular quantification using a 
general rat endothelial cell marker, and calculation of the vessel-positive area 
was performed in the ipsilateral and contralateral gray matter in vehicle- and 
bpV-treated animal groups. In brief, vessels in spinal tissue from bpV- and 
vehicle-treated animals were labeled via immunofluorescence with mouse anti-
rat endothelial cell antigen-1 (RECA-1, 1:200; ABD Serotec), a specific vascular 
marker, overnight at 4°C. The following day, the tissue was labeled with 
fluorescent secondary antibody and high power images acquired with an 
Olympus BX60 microscope, and PictureFrame software (Optronics). RECA-1+ 
area was measured using ImageJ software (NIH). Through modified methods 
previously published (Nakashima et al., 2008) the anatomically defined area of 
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ipsilateral gray matter containing clearly identifiable RECA-1+ vasculature was 
outlined in ImageJ. The area of the outlined region of interest was calculated by 
the software, and this area was defined as vasculature-positive area. Only areas 
of gray matter clearly containing morphological identifiable vasculature, as 
identified by RECA-1 labeling, were included in this assessment. 
 
Immunofluorescence Double Labeling  
Immunofluorescence double labeling was performed as previously described (Liu 
et al., 2006). Briefly, 1 day following SCI, 1 cm spinal tissue including the injury 
epicenter was removed after perfusion, and cryoprotected in 30% sucrose in 0.1 
M PBS. Cord segments were sectioned and prepared for staining as described 
above, and incubated with the following primary antibodies: mouse and rabbit 
anti-PTEN (1:100; Santa Cruz Biotechnologies), rabbit anti-phospho ribosomal 
protein S6 (ser 235/236) (1:400; Cell Signaling, Inc.), mouse anti-NeuN (1:200; 
Chemicon), a marker for neurons; mouse anti-CC1 (APC-7, 1:25; Calbiochem 
Inc.), a marker for oligodendrocytes; mouse anti-OX42 (Harlan Sera-lab), a 
marker for microglia; and rabbit and mouse anti- glial fibrillary acidic protein 
(GFAP, 1:200, Sigma), a marker for astrocytes. The following day, the sections 
were incubated with rhodamine- or fluoroisothiocyanate-conjugated goat anti-
rabbit or anti-mouse antibodies (1:200, Jackson ImmunoResearch Lab). Sections 
were coverslip mounted with Fluoromount G with Hoechst 33342 combined with 
the mounting medium (1:100) for nuclear staining. Pre-immune serum was used 
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as a control to confirm the specificity of the antibody. Images were obtained with 
a Nikon TE2000 laser scanning confocal microscope. 
 
Behavioral Testing 
For functional assessment, cereal rings of uniform shape, size, and flavor were 
provided and arm joint articulation (Martinez et al., 2009), movement, treat 
handling, and coordination were assessed while the animal ate the treat. Each 
rat was placed within and tested in a home cage, which promoted the most 
optimal conditions for assessing the animals’ behavior and performance. Using 
an 8 point scale, with 8 indicating normal ability and 0 representing no ipsilateral 
forelimb treat contact ability, the animals were tested before SCI (baseline), and 
once per week for 6 weeks following injury, and were scored on three separate 
trials with the three scores averaged. Treat manipulation was defined as obvious 
consistent coordinated handling of the treat by both forelimbs during eating. 
Tables 2 and 3 represent the scoring scale and sheet, respectively.   
     
Statistical Analysis 
To determine significance between two groups, a two-tailed unpaired Student’s t-
test was used. Statistical significance between multiple groups was determined 
using a one-way ANOVA with Tukey’s post-hoc analysis. All statistical values 
were calculated using GraphPad Prism 5.0 software (GraphPad, Inc.), with a p 
value < 0.05 considered statistically significant. 
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Table 2. Forelimb function assessment scale. 
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Table 3. Forelimb function assessment scoring sheet. 
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Results 
 
bpV(pic) promotes significant neuroprotection after cervical contusive SCI 
To assess whether bpV treatment promoted neuroprotection following injury, 
histological analysis was utilized. Six weeks post-injury, cresyl violet-eosin 
staining revealed the extent of the lesion, and the lesion volume, cavity, and 
spared tissue in the ipsilateral spinal cord were measured. bpV treated animals 
had significantly reduced ipsilateral lesion (21% ± 1.1 vs. 34% ± 3.0 SEM; p < 
0.01) and cavity volume (approx. 67% reduction; p < 0.05) compared to vehicle-
treated animals (Fig. 4 & 5). In comparison to the relative area of the ipsilateral 
cord, the spared tissue was significantly increased in bpV-treated animals 
compared to vehicle controls (79% ± 1.1 vs. 66% ± 3.0 SEM; p < 0.01). 
Additionally, bpV treatment reduced the amount of cavitation typically observed 
in subacute to chronic phases after contusive SCI, as seen in the vehicle-treated 
group (Fig. 5 & 6).   
Consistent with reduced lesion volume, bpV-treated animals exhibited a 
trend of more ventral horn motorneurons closer to the injury epicenter than 
vehicle-treated animals, with significantly increased motorneurons noted both 2 
mm rostral and caudal to the injury epicenter (Fig. 7 & 8). As vascular sparing 
and integrity have been attributed to bpV-mediated neuroprotection following SCI 
(Nakashima et al., 2008), using methods of vascular quantification modified from 
previous publication (Nakashima et al., 2008), RECA-1+ vascular area (mm2) was 
assessed in anatomical regions of interest (gray matter from transverse spinal 
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sections: 2 mm rostral and caudal, and at the injury epicenter (Fig. 9 & 10).  
Spinal cord RECA-1+ (vascular) gray matter area was significantly increased at 
the rostral region in bpV(pic)-treated rats compared to vehicle-treated animals (p 
< 0.01), as well as at the epicenter of the injury (p < 0.05).  
No difference in gray matter vascular area was observed caudal to the 
injury site (Fig. 10). The contralateral gray matter vascular area, as expected, did 
not exhibit differences between treatment groups either rostral or caudal to the 
injury. However, significantly more vascular area was measured in the bpV-
treated group within the contralateral gray tissue at the injury epicenter in 
comparison to the vehicle-treated group (p < 0.05) likely due to neuroprotection 
mediated by treatment (data not shown). 
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Figure 4. bpV(pic) reduced lesion size and cavitation following C5 
hemicontusion SCI. (A) Tissue extracted from rats 6 wks post-SCI 
demonstrated reduced lesion and cavitation through cresyl violet-eosin staining 
compared to vehicle treated animals. Images were obtained from 1 cm tissue 
with the injury epicenter. Scale bar = 1 mm. 
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Figure 5. Graphical representation showing statistically significant 
reduction in spinal tissue damage by bpV(pic). Lesion (A) and cavity (B) 
volumes, and increased spared tissue (A) following bpV(pic) treatment. 
Quantifications were from 1 cm tissue containing the injury epicenter. **, p < 0.01; 
*, p < 0.05. n = 4 – 5. Error bars = SEM. 
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Figure 6. 3D-reconstruction using Neurolucida software contour mapping 
from representative cases illustrating the neuroprotective effects of acute 
bpV(pic) therapy. 
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Figure 7. Acute bpV therapy reduced motor neuron loss following SCI.  
bpV(pic) treatment spared, on average, more ventral horn motor neurons than 
vehicle-treatment (A). Significantly more motor neurons were present in the 
ventral horn 2 mm rostral and caudal to the lesion epicenter of bpV(pic) treated 
animals. *, p < 0.05. n = 4 – 5. X-axis represents mm from epicenter. Error bars = 
SEM.   
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Figure 8. Photomicrographical representation showing cresyl violet-eosin 
stained ventral horns of spinal tissue extracted 6 weeks post-SCI. Sections 
shown are from 2 mm rostral to the epicenter and demonstrate the increase in 
motor neurons in bpV-treated animals over vehicle-treatment. Scale bar = 150 
μm. 
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Figure 9. Significant increase in ipsilateral gray matter vasculature rostral 
and at the epicenter of the injury. bpV(pic)-treated animals demonstrated 
significantly increased vascular (RECA-1)-positive area in the ipsilateral gray 
matter 2 mm rostral and at the epicenter of the lesion 6 weeks post-SCI. No 
significant difference was observed 2 mm caudal to the epicenter. **, p < 0.01; *, 
p < 0.05. n = 4 – 5. Error bars = SEM. 
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Figure 10. Photomicrograph of increased gray matter vasculature mediated 
by bpV(pic) after SCI. bpV(pic)-treated animals had significantly increased 
RECA-1-positive vasculature 2 mm rostral and at the epicenter of the lesion 6 
weeks post-SCI. * = central canal. Scale bar (Rostral & Caudal) = 100 μm; 
(Epicenter) = 150 μm. 
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Skilled forelimb articulation and coordination improved following bpV(pic) 
treatment 
To determine whether the observed neuroprotection mediated by bpV enhanced 
functional recovery, a novel forelimb behavioral assessment was used. During 
the 6 week behavior testing, animals that received bpV significantly recovered 
highly skilled forelimb function and coordination while eating cereal rings, 
compared to the vehicle-treated animals, using our independently-developed 
forelimb coordination and manipulation test (Fig. 11). Sham animals achieved 
perfect scores (8 = maximum score) overall during testing, as expected. bpV-
treated animals averaged a score of 6.94 ± 0.06, while vehicle-treated animals 
averaged a score of 4.43 ± 0.59 by the end of 6 weeks. Scores obtained during 
skilled forelimb use demonstrated a highly linear correlation with arm articulation 
ability (R2 = 0.88; Fig. 11), as scored as a subset from a forelimb locomotion test 
published and used by Martinez et al., (2009). Figure 12 depicts sham, injured, 
and injured rats treated with bpV performing this task. The red arrows point to the 
ipsilateral paw, and show functional status based on treatment. 
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Figure 11. bpV-treatment enhanced forelimb functional recovery. (A) By 6 
weeks post-injury, bpV(pic)-treated rats exhibited significantly enhanced forelimb 
function over vehicle-treated animals as scored using an 8-point treat 
manipulation behavioral scale (6.8 vs. 4.5). Sham animals scored at or near 
perfect (8 points) throughout the study. (B) Testing scores showed a positive 
linear correlation with arm joint articulation ability (R2 = 0.88). (C) Images 
portraying a rat grasping and manipulating a flavored cereal ring, the treat used 
in this assessment. **, p < 0.01; *, p < 0.05. n = 4 – 5. Error bars = SEM. 
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Figure 12. Images portraying a rat grasping and manipulating a flavored 
cereal ring, the treat used in this assessment. The red arrows are pointing to 
the ipsilateral forepaw following surgery. The rat’s forelimb and paw was severely 
impaired during this assessment following injury. The administration of bpV 
significantly improved the ability of the rat to coordinate forelimb movement and 
manipulate the treat with its forepaws. 
 
 
 
 
 
 
 
 
53 
 
 
Acute cell-specific expression profiles of PTEN and phospho-S6 after 
cervical SCI 
As we hypothesized that bpV may act through PTEN functional inhibition, 
immunofluorescence double-labeling of PTEN with various cell types and 
structures was employed to allow for identification of potential cellular targets 
affected by bpV treatment (Fig. 13). PTEN was highly expressed in motor 
neurons (Fig. 13A-C), CC1+ oligodendrocytes (Fig. 13G-I), and OX-42+ reactive 
microglia (Fig. 13J-L) after injury, though some minor expression was seen in 
reactive astrocytes post-SCI (Fig. 13D-F). As PTEN inhibition would promote 
upregulation of PI3K/Akt/mTOR signaling, cell-specific colocalization with the 
mTOR activity marker, phosphorylated ribosomal protein S6 (p-S6), was also 
performed. In general, p-S6 expression upregulation was observed in motor 
neurons (Fig. 14A-F) of injured animals, as well as hypertrophic reactive 
astrocytes (Fig. 14G-L) near the injury site. There was no obvious difference in p-
S6 expression change in CC1+ oligodendrocytes after injury (Fig.14M-P). 
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Figure 13. PTEN cellular localization following injury. (A – C) PTEN highly 
colocalized to MAP2+ neurons (D – F), however, PTEN only somewhat 
colocalized with GFAP+ hypertrophic astrocytes near the lesion (arrow), but 
highly localized to morphologically swollen axons (arrowhead). (G – I) CC-1+ 
oligodendrocytes and (M – O) OX-42+ reactive microglia also expressed 
considerable PTEN 1d following SCI. (J – L) PTEN highly colocalized to both 
smaller and swollen (arrow) degenerating axons within white matter tracts 
surrounding the injury. Observations were from tissue ~2 mm rostral to the injury 
epicenter. Scale bar = 100 μm. 
 
 
 
 
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Phospho-S6 cellular localization following injury. Like PTEN, 
phospho-S6 (p-S6) colocalized with many cell and structure types 1d following 
SCI within the injury penumbra (~2 mm rostral to the epicenter). Phospho-S6 was 
expressed very abundantly in (D – F) neurons, and (J – L) hypertrophic 
astrocytes following SCI, as indicated by arrows. (M – P) Oligodendrocytes highly 
expressed p-S6 before and after injury (arrows). Scale bar = 100 μm. 
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bpV(pic) enhances Akt/mTOR signaling, and reduces LC3 II/LC3 I ratio 
 
To quantify bpV’s effects on PI3K/Akt/mTOR pathway-related protein expression 
changes in the cervical spinal cord, Western blot analysis was performed on 
tissue from uninjured animals, as well as bpV-treated and non-treated animals. 
PTEN expression levels were not significantly different between sham and 1d 
following SCI, though a trend in increase was observed following injury (Fig. 15). 
bpV treatment showed no significant effect on PTEN expression levels (Fig. 15A 
& B). To determine whether SCI or bpV(pic) influenced PTEN’s antagonism of 
PI3K and downstream mTOR activity, phosphorylated Akt (p-Akt) and p-S6 levels 
were assessed. One day following SCI, p-Akt significantly decreased in injured 
spinal tissue (p < 0.01), while p-S6 expression significantly increased following 
treatment (p < 0.05). bpV treatment recovered p-Akt expression levels to near 
sham levels compared to injury-only and vehicle-treated animals (Fig. 15A & C) 
(p < 0.05), and elevated p-S6 expression further over sham (p < 0.01), but not 
significantly over injury-only, or vehicle-treated animals (Fig. 15A & D). As mTOR 
is a known regulator of autophagy, autophagosome formation was measured by 
quantifying downstream microtubule-associated protein light chain 3 (LC3) 
protein levels. A band shift during SDS-PAGE blotting is indicative of LC3 I to 
LC3 II conversion, and thus an increase in autophagic activity (Kabeya et al., 
2000). The ratio of LC3 II to LC3 I increased in untreated animals 1d after injury, 
though this ratio significantly reduced (p < 0.05) to near sham levels of 
expression following bpV(pic) treatment (Fig. 15A & E), suggesting a reversal of 
autophagic activity upregulation seen in following SCI (Fig. 16).  
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Figure 15. Effects of bpV(pic) on mTOR and autophagic protein analysis 1d 
post-SCI. (A) Western blot profiles from 1 cm spinal tissue with the injury 
epicenter collected from experimental animals 1d post-SCI. (B – E) Quantification 
of blots shown in A. (B) Total PTEN protein expression did not significantly 
change following injury, though a mild increase in expression was observed. (C) 
Phospho-Akt levels significantly decreased following injury, and are significantly 
increased following bpV(pic) treatment. (D) Downstream, p-S6 protein levels 
significantly increased following injury, and are enhanced further following bpV 
treatment. (E) LC3 II ratio to LC3 I, an indicator of autophagic activity, is 
increased following injury, and is significantly reduced following bpV(pic) therapy. 
*, p < 0.05; **, p < 0.01 (n = 4 – 5). Error bars = SEM. 
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Figure 16. bpV(pic) reduced neuronal autophagosome aggregation.  
Vehicle-treated rats exhibited dense intracellular LC3-positive autophagosome 
aggregation in neurons within the injury penumbra ~2 mm rostral to the injury 
epicenter (arrows). Treatment with bpV promoted a decrease in neuronal 
autophagosome clustering. Scale bar = 50 μm. 
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Discussion 
 
Neuroprotection and functional recovery promoted by bpV 
Inhibition of PTEN’s activity using bpV has proven neuroprotective in 
experimental CNS injury or disease models, including ischemia-reperfusion injury 
(Zhang et al., 2007a), SCI (Nakashima et al., 2008), and Parkinson’s disease 
(Yang et al., 2007). These reports support our findings of enhanced 
neuroprotection and functional recovery seen in this study. By 6 weeks post-
injury, bpV(pic) drastically reduced lesion and cavity volume, while increasing 
spared tissue, including vasculature, as well as skilled forelimb function over 
vehicle-treated control animals. The enhanced amount of vasculature-containing 
gray matter tissue could logically result from overall reduction of lesion and 
spread of secondary cell death observed following bpV therapy, or a stimulation 
of angiogenesis following this treatment, due to suppression of PTEN activity and 
subsequent upregulation of PI3K signaling (Wen et al., 2001, Liu et al., 2011, 
Park et al., 2011). A second explanation is that vascular sparing actually 
contributes to the overall neuroprotection effects, a hypothesis proposed by 
Nakashima et al. (2008) after observing a similar phenomenon following 
bpV(phen) treatment for SCI. In support of this explanation, a recent study by 
Han et al., showed that angiopoietin-1 and synthetic C16 peptide treatment 
spared vasculature by targeting the vascular endothelium, leading to reduced 
inflammation, diminished white matter loss, and functional recovery following SCI 
(Han et al., 2010). Concerning bpV’s influence on vasculature, more analysis of 
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the role of vascular sparing or regrowth in anatomical and functional outcome is 
necessary to elucidate explanations for increased vasculature witnessed at later 
time points following treatment.   
 bpV also promoted significantly increased forelimb functional ability in 
comparison to vehicle treated animals beginning two weeks post-injury (p < 0.05) 
with improvement observed until the end of testing (p < 0.01). These results 
corresponded well to the significant neuroprotection observed in this study. While 
eating, rats utilize proprioceptive ability to manipulate and eat through 
coordinated and articulated forelimb activity, allowing for a more sensitive 
assessment of the injured forelimb’s functional ability. Also, the innate motivation 
of the rats to eat the treats is high, requiring no training and allowing for easy 
repetition for multiple trials during each testing period without fasting the animals. 
A similar, though separately developed test was recently published by Irvine et 
al., demonstrating the need for reliable sensitive assessments of overall fine 
forelimb function following cervical SCI (Irvine et al., 2010). The details of their 
test also support the validity of our design, enhancing confidence that the 
increased performance during our forelimb assessment after bpV(pic) treatment 
is genuine. Altogether, the reduced cell loss, lesion volume, and increased 
spared tissue positively correlate with the enhancement of forelimb functional 
ability witnessed 6 weeks after SCI, further supporting our data and hypotheses.   
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Linking bpV to Akt/mTOR signaling following cervical spinal injury 
Though no significant PTEN expression change was observed, our results show 
that PTEN is highly expressed in neurons, CC1+ oligodendrocytes, and activated 
microglia 24 hours after injury. PTEN expression was observed in reactive 
astrocytes, albeit minimally, as well, after cervical SCI, suggesting that multiple 
cell types may be targets for bpV(pic) action. Overall p-Akt levels relative to pan-
Akt decreased in the cervical spinal tissue analyzed via Western blot (Fig. 15A & 
C), suggesting that PTEN activity may increase post-SCI. However, an increase 
in p-S6 was observed in neurons and increasingly hypertrophic astrocytes near 
the injury site, suggesting that neurons may upregulate mTOR activity for protein 
synthesis as a neuroprotective response, and glia (Fig. 14) both for 
neuroprotection and to initiate and enter a reactive state following the injury, as 
discussed below. Despite the increase in p-S6 seen in reactive astrocytes, no 
significant difference in GFAP reactivity between treated and non-treated animal 
groups was observed 6 weeks post-SCI (data not shown). Interestingly, 
oligodendrocytes highly expressed p-S6 both pre- and post-injury (Fig. 14M-P), 
suggesting this mechanism may serve both a neuroprotective, as well as 
perhaps a myelin-related function in these cells. PTEN expression is reported to 
be essential for oligodendrocyte maintenance of myelin and axonal integrity, 
though not for remyelination as demonstrated through PTEN knock-out 
experiments (Harrington et al., 2010).   
 It is quite striking that neurons and glia drastically upregulate p-S6 
following SCI, contradictory to expectations based on reports of benefits from 
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PTEN inhibition following CNS injury. The discrepancy between Akt activity 
decrease and ribosomal protein activity increase may result from two different or 
interacting mechanisms via cross-talk between PI3K and MAPK signaling. It has 
been shown that following SCI, active phosphorylated Erk increased dramatically 
and rapidly (Lu et al., 2010). Activated isoforms of Erk are known contributors to 
p70S6 kinase (p70S6K) upregulation along with mTOR (Lehman and Gomez-
Cambronero, 2002), which could explain the significant increase in p-S6 following 
SCI, despite the down-regulation of p-Akt. Active Erk is also known to activate 
mTOR through upstream tuberous sclerosis complex 2 (TSC2) inhibition (Ma et 
al., 2005), and on p90 ribosomal protein kinase (Dummler et al., 2005) which 
could also contribute to upregulated p-S6.  
 The discrepancy between the decrease in p-Akt and downstream 
upregulation of p-S6 may have resulted from an early increase in p-Akt leading to 
the delayed downstream effect of increased mTOR activity through p-S6 
phosphorylation. Yu et al. (2005) showed that Akt phosphorylation increased in 
penumbral neurons 8 hrs following SCI, with a down regulation observed at time 
points afterward. Ribosomal protein S6 can be phosphorylated by p70S6K 
through Akt-mediated TSC1/2 inhibition and subsequent activation of mTOR. The 
timespan of this sequence of events may explain the elevated p-S6 observed in 
this study at 24 hrs post-injury. Also, p70S6K is known to provide negative 
feedback on PI3K/Akt to regulate continuing activation of this signaling axis 
(Manning, 2004). Therefore, as mTOR activation of p70S6K increases, this 
molecule may serve to prevent further phosphorylation and activation of Akt 
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contributing to the decreased p-Akt levels observed at 24 hrs after SCI. 
Nonetheless, the enhancement in p-Akt and p-S6 levels provide a potential 
mechanistic explanation of the action of bpV(pic) by implicating an mTOR-
dependent and independent influence in the neuroprotection and functional 
recovery observed during this study.   
 This dual-pathway targeting of translational upregulation through S6 
activation may be a method of promoting an endogenous neuroprotective 
response, contributing to various cellular activities triggered by the insult. This 
could also explain the upregulation of mTOR activity implicated in astrocyte 
reactivity witnessed here and elsewhere in response to spinal injury (Codeluppi 
et al., 2009). PTEN expression was not visually abundant in non-injured 
astrocytes, but was detected at low-levels in reactive astrocytes 1d post-injury, 
consistent with reports observing PTEN in astrocytes early in reactive 
astrogliosis, decreasing as reactivity peaks (Cho et al., 2002). Though overall p-
Akt levels decrease post-injury near the injury site, the increase in both p-Akt and 
p-S6 levels after bpV treatment suggest an enhanced benefit of upregulating 
both pathways, either through an endogenous neuroprotective feedback 
mechanism, or other mechanism promoting amplification of p-S6 and other cell 
responses observed following SCI.  
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Downregulation of autophagy following bpV treatment 
Enhancement of endogenous cell survival mechanisms, such as autophagic 
activity, can rapidly stabilize the cell in response to hypoxic, ischemic, and 
inflammatory conditions. Autophagy is a normal cellular phenomenon required for 
degradation of organelles and proteins, and can be increased for energy 
acquisition when under cell or nutrient stress. Autophagy dysregulation, however, 
has been implicated as a cause of autophagic, or Type II programmed cell death 
following SCI (Kanno et al., 2009, Kanno et al., 2011). In contrast, supporting 
mTOR upregulation as a trigger for increased autophagic activity, p70S6K has 
been shown to enhance autophagic activity following mTOR activation (Scott et 
al., 2004). However, this endogenous protection mechanism may not suffice to 
spare the cells from delayed death post-SCI, or perhaps the stimulation of 
autophagic activity proceeds from beneficial to detrimental, ultimately leading to 
programmed cell death. A continuum of biological processes within cells 
influenced by SCI including autophagic activity is likely in describing different 
stages leading to programmed cell death. 
 Our results suggest that bpV treatment may serve as an autophagic 
“switch” by forcing increased mTOR activation, and enhancing the inhibitory-
actions of mTOR on autophagy. Overactivation of p70S6K is not associated with 
increased autophagic activity, and mTOR can act directly through regulation of 
autophagy-related proteins resulting in non-p70S6K dependent control of this 
process (Scott et al., 2004), supporting our findings and aiding in our 
interpretation of these results. If autophagic activity plays a role in neuronal 
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programmed cell death, then bpV(pic) may act through PI3K signaling and 
mTOR to downregulate this process, preventing the transition towards cell loss.   
 
Considerations for bpV as a therapy for SCI 
Although bpV(pic) is an accepted inhibitor of PTEN activity, it may also exhibit 
other unknown functions following treatment that may or may not contribute to or 
antagonize effects directly investigated in this study. Bisperoxovanadium 
compounds are inhibitors of protein-tyrosine-phosphatase (PTP) activity (Posner 
et al., 1994), some others of which may be influenced by such therapy in the 
complex experimental system of an animal model. One example involves indirect 
promotion of PTEN activity by bpV-mediated inhibition of the PTP, Src homology 
region 2 domain-containing phosphatase-1 (Shp-1), which is known to bind, 
dephosphorylate, and activate PTEN (Lu et al., 2003). Src protein kinases serve 
several roles, one of which being involved in promoting cell survival through 
PI3K/Akt signaling (Thomas and Brugge, 1997). Therefore, bpV could interfere 
with Src-related protein modulation of PTEN activity in addition to, or separate 
from, direct PTEN functional inhibition. Additionally, PTEN deletions and 
mutations are commonly associated with cancer, as the loss of PTEN 
antagonism of PI3K dysregulates the balance between cellular senescence and 
proliferation (Suzuki et al., 1998, Dahia et al., 1999, Stiles et al., 2002). To 
minimize such concerns, short-term bpV-therapy allows strict control of timing, 
dosing, and withdrawal of use of the drug. In the present study, a one week 
treatment regimen of bpV(pic) promoted significant long-term neuroprotective 
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effects and functional abilities of the forelimb following treatment, and such a 
short therapeutic time period should have minimal impact on or threat of tumor 
formation, compared to long-term PTEN-activity reduction or PTEN deletion. In 
conclusion, acute administration of 400 ug/kg bpV(pic) following cervical 
contusive SCI afforded anatomical and functional forelimb benefits, which are 
considered very important factors for victims suffering from cervical injuries 
(Anderson, 2004). This report is a novel step toward understanding the 
mechanism and benefits of bpV treatment on injured spinal tissue and associated 
functional outcome, and a foundation for future studies utilizing bpV 
combinational therapies for improving anatomical and functional recovery after 
cervical SCI. 
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CHAPTER 3 
AIM 2 
 
IDENTIFICATION OF SPECIFIC MECHANISMS OF BISPEROXOVANADIUM 
ACTIVITY IN MEDIATING EFFECTS ON SPINAL NEURONS  
IN VIVO AND IN VITRO FOLLOWING INJURY  
 
Hypotheses: 1) Phospho-Akt changes are similar in spinal neurons as observed 
for the total tissue following SCI. 2) bpV(pic) is protective against primary neuron 
death following trauma and enhances Akt and ribosomal protein S6 
phosphorylation in vitro, helping support our previous cell signaling and 
neuroprotective findings in vivo. 
 
Introduction 
Though our knowledge of cellular responses to injury is incomplete, exogenous 
promotion of neuroprotection and recovery using a readily-available and fast 
acting therapeutic would be valuable for slowing secondary injury and its 
destruction of initially spared tissue. Consequently, understanding mechanisms 
by which such treatments act is as important as identifying the therapies 
themselves. 
Modulating the activity or expression of the PTEN (Park et al., 2008, Liu et 
al., 2010, Sun et al., 2011), and neuroprotection following central nervous system 
(CNS) injury and neurodegeneration (Li et al., 2009). As described in Chapters 1 
and 2, PTEN is a known antagonist PI3K, preventing PIP3 from promoting 
phosphorylation and activation of the pro-survival kinase Akt. Inhibiting PTEN 
disinhibits PI3K signaling leading to improved cell survival, tissue sparing, and 
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functional recovery (Walker et al., 2012) potentially through reducing delayed 
destructive processes.   
We demonstrated that PTEN expression does not significantly change 24 
hours post-SCI, though phosphorylated (active) Akt decreases, suggesting 
PTEN’s lipid phosphatase activity and antagonism of PI3K increases within 
injured tissue following SCI. Thus, our prior evidence supports the hypothesis 
that PTEN activity promotes cell death following SCI. We identified neurons as 
potential targets of bpV as they expressed PTEN prior to and after injury, and 
treatment with a potent PTEN inhibitor, bpV(pic) (Schmid et al., 2004), induced 
significant ventral horn neuron survival following cervical hemi-contusion SCI. 
Although whole tissue protein analysis revealed significant reduction in Akt 
phosphorylation in the proximity of the injury site 1 day post-SCI, it is unclear 
whether this suppression is sustained in surviving spinal neurons following injury. 
Also, our previous research did not confirm whether bpV(pic) acted directly on 
neurons in promoting their survival following SCI. Furthermore, our results 
suggested that bpV(pic) acted through PI3K/Akt signaling post-injury, however, 
our evidence was correlative and did not reveal whether bpV(pic) operated via 
this mechanism specifically in neurons. We therefore designed the present study 
to assess the extent of the modulation of Akt phosphorylation following SCI, 
extend our understanding of bpV(pic)-mediated neuroprotection, and more 
effectively determine whether bpV(pic) acts on PTEN and PI3K/Akt signaling in 
spinal neurons following traumatic injury.  
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Materials and Methods 
 
Animals and surgical procedures 
Adult female Sprague-Dawley rats (200 – 250 g, Harlan) (n = 40) were 
maintained under controlled conditions with a 12:12 light:dark cycle with ad 
libitum water and food access. Prior to surgery, animals were anaesthetized 
intraperitoneally (IP) with a ketamine/xylazine cocktail ([87 mg/kg]/[12 mg/kg]), 
and received laminectomy only (sham operation) or unilateral cervical SCI 
performed as previously published (Walker et al., 2012). In brief, a customized 
device was used to stabilize the 5th cervical vertebrae and a partial unilateral 
laminectomy exposed the right side of the cord leaving the dura intact. The 
NYU/MASCIS Impactor (Gruner et al., 1992) (2.5 mm tip, 10g weight, 12.5 mm 
height) produced a moderate unilateral injury (Gensel et al., 2006). Sham 
animals underwent anesthesia and surgery, but were excluded from injury. 
Animals received 5 mL 0.9% saline subcutaneously for hydration and were 
observed over a 24 hr recovery period in temperature controlled housing. All 
animal procedures and surgeries were approved under the Guide for the Care 
and Use of Laboratory Animals (National Research Council) and the Guidelines 
of the Indiana University School of Medicine Institutional Animal Care and Use 
Committee. 
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Primary spinal neuron culture and treatment 
Primary spinal cord neurons were obtained from Sprague Dawley rat E15 
embryo spinal cords according an established protocol (Jiang et al. 2006). In 
brief, E15 rat spinal cords were isolated and placed in Leibovitz’s L-15 medium 
(Gibco). Meninges were carefully removed, the spinal cords were cut into small 
pieces and dissociated with 0.05% trypsin/EDTA for 15-20 min at 37o C and 
gently triturated. After adhering at 37o C for 30 min to eliminate glial cells and 
fibroblasts, neurons were plated on poly-L-lysine pre-coated 48-well plates 
(Corning). Neurons were incubated in a humidified atmosphere containing 5% 
CO2 at 37
o C with DMEM +10% heat-inactivated fetal calf serum + 5% heat-
inactivated horse serum + 2 mM glutamine. After 16 hours, medium was replaced 
with Neurobasal medium with 2% B27, 1% N2 and 2 mM glutamine (all from Life 
Technologies, Inc.). On day 3 in vitro, 5 µM cytosine-β-D-arabinofuranoside 
(Sigma-Aldrich) was added for 24 h to inhibit glia cell proliferation. Cells in 48-
well plates were cultured with 200 μL medium until experimentation. With this 
culture protocol, a purity of greater than 87% spinal cord neuron population was 
obtained by 7 DIV. All experiments were performed between 7 and 10 DIV.  
 
In vitro traumatic neural injury model  
Primary spinal neurons were cultured as described. At the time of 
experimentation, cells received either a fresh medium change (control) or were 
mechanically damaged by a monolayer scratch injury model modified from 
previous studies (Zhao et al., 2012). In summary, an 18 gauge surgical needle 
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was flattened to reduce the sharpness and increase the surface area of damage, 
and distinct grid patterns of scratches were performed in either 48-well or 6-well 
culture plates containing 7-10 DIV mixed spinal neuron culture. Each scratch was 
approximately 200 μm wide, and variably spaced according culture well type. 
This needle and scratch designs were experimentally determined for optimal use 
in producing graded injury over time, and served as a useful and responsive 
model for experimental treatment with bpV(pic) and other signal pathway 
inhibitors. 
 
Assessment of bpV(pic) treatment effects on spinal neurons 
In wells selected for experimental treatment, a 45 min pre-treatment with 
experimentally-determined doses of 100 nM PTEN inhibitor bpV(pic) (Enzo Life 
Sciences) in 0.9% saline, 20 μM PI3K-inhibitor LY294002, 25 nM mammalian 
target of rapamycin (mTOR) inhibitor rapamycin (LC Laboratories), or 
combinations of the above was implemented. Following pre-treatment, cells were 
left uninjured (controls) or received scratch injuries and left in culture for 
designated periods of time depending on the experiment. After experimental 
treatment, supernatant was collected for cell death assays and cells were either 
prepared for Western blot analysis or immunocytochemistry.   
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Propidium iodide (PI) neuron death labeling 
Hoechst 33342 (Sigma) was added to culture wells and plates were incubated at 
37o C and 95% O2/5% CO2 for 10 min to label all cell nuclei. Plates were then 
incubated with PI (Sigma) at room temperature for 15 min to label nuclei of dead 
cells. Following PI incubation, medium was extracted and cells were washed with 
0.01 M PBS, followed by a 10 min treatment with 4% paraformaldehyde (PFA) in 
0.1 M PBS to fix the cells. Cells were then washed with PBS and labeled with 
AlexaFluor 488-conjugated β-III-tubulin primary antibody (Millipore) for 1 hr in 
PBS-T for neuron labeling + 10% normal goat serum to prevent non-specific 
binding. Cells were then washed 3 x 5 min with PBS-T and covered with PBS in 
the well for imaging. 
 
Cell death assay 
To assess the damage and death of cultured spinal neurons, lactase 
dehydrogenase (LDH) release assay was performed on the cells’ supernatant 
per the manufacturer’s instructions (Promega, Cytotox 96). Briefly, 50 µL medium 
was removed from each well with cultured neurons in a 48-well plate following 24 
hr injury experiment, and transferred to corresponding wells of an empty flat-
bottomed 96-well plate. Supplied LDH substrate mix (50 µL) was added to each 
well, and the plates were left in the dark for 30 minutes. Afterward, reaction Stop 
Buffer was added to end LDH enzyme activity, and the plates were read on a 
plate reader at an absorbance 490 nm. A numerical absorbance value for each 
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well was calculated as a measure of the amount of LDH release by the neurons 
with and without scratch injury. 
 
Western Blotting 
Spinal neurons used for protein analysis were cultured on 6-well plates as 
described above. Approximately 1.5 x 106 cells/well were lysed in RIPA Lysis 
Buffer (25mM Tris-HCl [pH 7.6], 150mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS + 0.5 M EDTA and 1% Halt inhibitor with a Dounce 
homogenizer (20X up-and-down) and left on ice for 15 minutes. Then, the lysates 
were centrifuged for 15 min at 13,000 rpm. Supernatants were extracted and 
protein concentrations were determined using the Bradford method (Bradford, 
1976). Samples were prepared with 6x sample buffer, loaded on 8-10% SDS-
polyacrylamide gels, and separated via electrophoresis. Proteins were 
transferred onto polyvinyldine fluoride (PVDF) membranes, and blocked against-
non-specific antibody binding with Li-Cor Odyssey blocking buffer (Li-Cor, 
Lincoln, NE) for 1 hr. Following blocking, the membranes were incubated with 
primary antibody diluted in blocking buffer with 1% Tween-20 overnight at 4o C. 
Membranes were then washed with 0.01 M phosphate buffered saline (PBS) + 
1% Tween-20 (PBS-T), and incubated with secondary antibody (goat anti-mouse 
IR Dye800 or goat anti-rabbit IR Dye680 (Rockland Immunochemicals Inc., 
Gilbertsville, PA) diluted in blocking buffer + 1% Tween-20 for 1 hr at room 
temperature. After washing with PBS-T, membranes were scanned using a Li-
Cor Odyssey infrared scanner, and images captured using Image Studio 2.0 
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software (Li-Cor). Densitometry of specific bands was performed using ImageJ 
software (NIH, Bethesda, MD). 
Tissue protein analysis from in vivo experiments followed procedures 
described previously (Xu et al., 1998b) with modification. Briefly, a 10 mm spinal 
cord segment containing the injury epicenter (5 mm rostral and caudal to the 
epicenter) was removed for protein extraction 24 hours following SCI. Equal 
protein concentrations from each sample was loaded onto 8-10% polyacrylamide 
gels, separated by SDS-PAGE, and transferred to a PVDF membrane. The 
membranes were immunoblotted with the following primary antibodies: 
monoclonal mouse-anti PTEN (1:200); rabbit anti-phospho-PTEN (ser 380, 
1:500), a marker for the inactive form of PTEN; polyclonal rabbit anti-phospho 
Akt (ser 473) (1:1,000), a marker used for assessing PTEN and PI3K activation; 
monoclonal mouse anti-pan Akt (1:1,500); polyclonal rabbit anti-phospho 
ribosomal protein S6 (ser 235/236) (1:400); cleaved caspase 3 (1:500) a marker 
for apoptotic cell death (Cell Signaling, Inc.); mouse anti-β-tubulin (1:1000, 
Sigma-Aldrich) as a loading control. Membranes were incubated with a 
secondary goat anti-rabbit or anti-mouse fluorescent IR680 or IR800 secondary 
antibody (1:10,000; Rockland) and visualized with the Li-Cor Odyssey system 
and software as described. Quantification of detected bands was performed by 
densitometry using ImageJ software (NIH). 
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Histological Preparation 
Tissue was collected six weeks post-injury and processed as previously 
published (Liu et al., 2006, Walker et al., 2012). In brief, a 1 cm segment of 
cervical cord including the injury epicenter was dissected and sectioned 
transversely at 20 μm thickness on Superfrost Plus slides (Fisher Scientific) 
using a cryostat (Leica). Serial sections with an interval of 0.5 mm along the 
length of the cord were used spanning the entire. A set of slides were stained 
with cresyl violet/eosin to identify the lesion epicenter and 2 mm rostral and 
caudal to the epicenter. Adjacent sections in this penumbral region were selected 
for immunofluorescence labeling to determine the pattern of p-Akt expression in 
surviving near-lesion neurons during the first week post-SCI. 
 
Immunofluorescence Double Labeling  
Immunofluorescence double labeling was performed as previously described (Liu 
et al., 2006, Walker et al., 2012). Briefly, 1 day, 3 days, and 7 days following SCI, 
1 cm spinal tissue including the injury epicenter was removed after perfusion, 
and cryoprotected in 30% sucrose in 0.1 M PBS. Cord segments were sectioned 
transversely at 20 µm thickness, mounted on Superfrost slides and prepared for 
immunostaining as described previously (Walker et al., 2012). Tissue sections 
were incubated with the following primary antibodies: mouse anti-NeuN (1:200, 
Chemicon, Inc.), a marker for neurons, and rabbit anti-phospho-Akt (ser473) 
(1:100, Cell Signaling). The following day, the sections were incubated with 
rhodamine-conjugated goat anti-rabbit or fluoroisothiocyanate (FITC)-conjugated 
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anti-mouse fluorescent secondary antibodies (1:200, Jackson ImmunoResearch 
Lab). Sections were coverslip mounted with Fluoromount G (Southern 
FluoroMount). Pre-immune serum was used as a control to confirm antibody 
specificity. Images were obtained at identical settings with an Olympus BX60 
epifluorescent microscope.  
 Fluorescent intensity of p-Akt in motor neurons 1.5 mm to 2 mm rostral to 
the epicenter (in the injury penumbra) was performed using ImageJ. This was 
achieved by converting the images to grayscale, outlining NeuN/p-Akt double 
labeled neurons of the ventral horn, and measuring the integrated density (ID) of 
p-Akt labeling of the neurons. Background values were obtained from 5 
identically sized sample areas of tissue adjacent to the quantified neurons, and 
an average background ID was calculated. The measured neuron ID was divided 
by the mean background ID to achieve neuron ID signal to background ID ratio 
values for each neuron. Approximately 10 motor neurons 1.5 to 2 mm rostral to 
the epicenter were measured per animal, and the signal/background ratio was 
averaged for all measurements from each animal, and all animals per group. 
 
Statistical Analysis 
A two-tailed unpaired Student’s t-test was used to determine significance 
between two groups. Statistical significance between multiple groups was 
determined using a one-way ANOVA with post-hoc analysis. All statistical values 
were calculated with GraphPad Prism 5.0 software (GraphPad, Inc.), with a p 
value < 0.05 considered statistically significant. 
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Results 
 
Changes in PTEN and p-Akt expression/activation following SCI 
Supporting previous observations, overall PTEN expression did not significantly 
change in injured spinal tissue following cervical SCI; however, PTEN activity 
level, depicted as a ratio of total PTEN to phospho-PTENser380 significantly 
increased by days 3 and 7 post-injury (3d, 71.4% increase; 7d, 57.1% over 
sham; p < 0.05) (Fig. 17A & C). Also corroborating our previous data, Akt 
phosphorylation decreased significantly by day 1 (39.1% decrease), and 
maintained a low expression pattern throughout the first week (Fig. 17B & C). 
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Figure 17. PTEN activity increased while Akt activity decreased following 
cervical SCI. By 3d & 7d post-SCI, PTEN activity as a measure of active PTEN 
over inactive p-PTEN significantly increased (A & C). Conversely, phospho-Akt 
decreased significantly by 1d (p < 0.01) and continued through 7d post-SCI (p < 
0.001) (B & C). *, p < 0.05; **, p < 0.01; ***, p < 0.001 (n = 4 – 6). 
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bpV decreased caspase 3 activity and increased GSK3β phosphorylation 
after SCI 
In assessment of bpV(pic) effects on apoptotic cell death, caspase 3 activity was 
assessed through Western blot 1d following injury. SCI significantly increased 
caspase 3 activity (67.1%) at this time point (p < 0.01 compared with sham), and 
treatment with saline vehicle did not influence injury-mediated caspase 3 activity 
(Fig 18A & C). Treatment with bpV(pic) during the 24 hour period post-SCI did 
significantly reduce caspase 3 activity (27.3%) (p < 0.05) to approximate levels 
observed in sham animals. To support the hypothesis that bpV(pic) increased Akt 
activity, phosphorylation of GSK3β at serine 9 was examined. Treatment with 
bpV(pic) significantly increased GSK3β phosphorylation at this residue over 
endogenous levels by 1d following SCI (Fig. 18B & C, p < 0.05). Sham animals 
exhibited high levels of p-Akt in spinal motor neurons (Fig. 19A-C); however, in 
SCI animals, expression decreased considerably and declined significantly by 7 
days post-injury (Fig. 19B, p < 0.05) as shown through immunofluorescence 
double-labeling of p-Akt with neuronal marker NeuN in surviving neurons ~1.5 
mm distal to the epicenter (Fig. 19 C-F”). 
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Figure 18. bpV(pic) decreased injury-mediated caspase-3 and GSK3β 
activities 1d after SCI. Cervical hemicontusion significantly increased cleaved 
caspase-3 (A & C) (p < 0.01) and bpV treatment, but not saline, significantly 
reduced this elevation (p < 0.05). Likewise, saline treatment did not alter SCI 
mediated p-GSK3β levels, the inactive form, but bpV did elevate p-GSK3β, 
although the difference was not statistically significant (B & C). *, p < 0.05; **, p < 
0.01; ***, p < 0.001 (n = 4 – 6). 
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Figure 19. Phospho-Akt decreased in ventral horn neurons following SCI. 
Neurons from the ventral horn region shown in (A) exhibited a time-course 
decrease in p-Akt the first week post-injury (B). Sham neurons showed high 
expression (C – C”), although this reduced by 1 day (D – D”) and continued 
through day 3 (E – E”) and day 7 (F – F”). Neurons with notable p-Akt changes 
are indicated by white arrowheads. Scale bar = 50 µm. 
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bpV reduced damage induced by a traumatic neuron injury in vitro 
To confirm bpV(pic)-mediated neuroprotective effects in spinal neurons, we 
employed an established purified spinal neuron culture protocol (Jiang et al., 
2006). To mimic the traumatic mechanical injury inflicted on spinal tissue and 
induce extended secondary cell damage as observed following SCI, we used a 
scratch injury model to inflict trauma to wide paths of neurons and neurites, while 
leaving adjacent neurons intact. The scratch patterns used in 48- and 6-well 
culture plates is shown in Fig. 20B & C. The damage path width was 
approximately 200 µm as show in comparison to other scratch techniques (Fig. 
20A). Neuronal cultures resembled the representative micrograph displayed in 
Fig. 20A. This model caused rapid and continued cell damage, and LDH release 
from the cells continued to increase to 24 hr post-injury (Fig. 21A). At 24 hr 
following scratch injury, cell death was most evident near the injury site as 
represented by numerous PI positive cells as compared to non-injured cells (Fig. 
21C). As observed in a contusive SCI model in vivo, bpV(pic) demonstrated 
neuroprotective effects on injured primary spinal neurons in culture. Acute LDH 
release was decreased by100 nM bpV(pic) measured 6 hr post-injury (Fig. 21B, 
p < 0.05). Corroborating this result, bpV reduced PI positive cells by 24 hr post-
injury (Fig. 21C).  
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Figure 20. An in vitro primary neuron scratch injury model to replicate 
traumatic SCI in vivo. Primary spinal neuron cultures from E15 rats were 
utilized for replicating neuronal damage observed following SCI in live animals 
(A). A grid pattern was used in both 48-well plates for assays and 
immunocytochemistry (B) and 6-well cultures and protein analysis (C). 
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Figure 21. bpV(pic) prohibited significant cell death caused by scratch 
injury in primary spinal neurons. The applied scratch injury model produced a 
temporal increase in cell death of primary neurons as assessed through LDH 
release over 24 hrs (A). Application of 100 nM bpV(pic) significantly reduced LDH 
release (B), and reduced propidium iodide labeling as a measure of dead cells 
(C). Dashed lines indicate the scratch area. *, p < 0.05; **, p < 0.01; ***, p < 
0.001 (n = 3). 
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bpV(pic) stimulated activation of Akt and mTOR in injured spinal neurons 
Upon confirmation of the compound’s protective effects in this injury model, we 
performed experiments to verify 1) that injury induced changes in Akt and/or 
mTOR signaling, and 2) whether bpV(pic) acted on PTEN and PI3K/Akt signaling 
in primary spinal neurons following injury. At 30 min following injury, Akt activity 
significantly decreased by ~20% (p < 0.05) (Fig. 22A). Treatment with 100 nM 
bpV(pic) significantly elevated Akt activity (36%) in injured neurons at 30 min 
post-scratch in vitro (Fig. 22A, p < 0.05), and induced a 25% increase in S6 
activity over injury level (Fig. 22B). 
To validate the activity of bpV(pic) on PI3K/Akt/mTOR signaling, 
experiments were carried out using the PI3K inhibitor, LY294002 and mTOR 
inhibitor, rapamycin on injured spinal neurons. When neurons were treated with 
100 nM bpV(pic) and LY294002, the bpV-mediated increase in p-Akt at 30 min 
was significantly inhibited (86% decrease, Fig. 22A, p < 0.001). Downstream 
mTOR activity enhanced by bpV(pic) was also reduced (86% decrease), as 
measured by S6 activity following PI3K inhibition (Fig. 22B, p < 0.01). Combined 
with rapamycin treatment, bpV(pic)-associated increase in S6 activity was also 
diminished in injured neurons, as expected (Fig. 22B).  
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Figure 22. Injury and bpV-mediated effects on Akt and ribosomal protein S6 
phosphorylation. (A) Akt phosphorylation (p-Akt) significantly decreased 
following scratch injury, and bpV significantly inhibited this reduction and 
increased p-Akt over control levels. PI3K inhibitor LY294002 blocked bpV’s 
effects. (B) Phosphorylation of ribosomal protein S6 was also increased by bpV 
following scratch injury (p < 0.05), and this effect was inhibited by both PI3K 
inhibition and inhibition of mTOR by rapamycin. *, p < 0.05; **, p < 0.01; ***, p < 
0.001 (n = 3). 
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Discussion 
Our results and confirmation of the neuroprotective and cellular signaling effects 
of bpV following traumatic contusive SCI and a spinal injury model in vitro are 
supported by evidence from multiple nervous system disease and injury studies 
(Zhang et al., 2007a, Nakashima et al., 2008, Song et al., 2010, Sury et al., 2011, 
Mao et al., 2013). Our study is novel as it is the first to examine the effects of 
bpV(pic), or any bpV compound, on injured isolated spinal neurons in vitro, and 
compare the effects of injury and bpV treatment on PI3K/Akt axis signaling to 
spinal neurons in vivo. As both Akt activation and bpV therapies have been 
widely demonstrated to have survival-enhancing effects, our results expand the 
knowledge of this signaling pathway and bpV-related effects on the PI3K/Akt 
signaling response in trauma-inflicted spinal neurons following SCI. 
Neuroprotection positively correlates with functional recovery, and enhancing our 
understanding of how to promote neuron survival, and the mechanism by which 
this benefit is achieved in animals and in vitro, provides information and tools for 
further research into improving functional outcome following SCI. 
Yu et al. demonstrated that peripheral neurons up-regulated Akt 
phosphorylation significantly by 8 h following SCI followed by a rapid down 
regulation by 24 h post-injury (Yu et al., 2005). Here we show that penumbral 
neurons downregulate p-Akt by 1d following cervical contusion injury, a pattern 
that continued throughout the first week after SCI. The similar neuronal Akt 
phosphorylation response pattern and the whole spinal tissue downregulation of 
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p-Akt suggests that neurons may be the primary cells influencing Akt activity 
following SCI. Brief inspection of Akt phosphorylation in glial cells in the region of 
the studied neurons was not conclusive; however, additional research is being 
performed to further assess the signaling changes in glia following injury and bpV 
treatment. Though Yu and colleagues examined motor neurons 3-6 mm distal to 
the injury site and we examined such cells approximately 1.5 mm from the 
epicenter, the overall trend is comparable. The neurons we examined survived 
the initial necrotic death within gray matter at and around the epicenter of injury 
during the first day post-SCI (Ek et al., 2010). Due to their proximity to this 
region, they likely were directly affected by the spread of secondary damage to 
tissue and adjacent cells, which may have altered their response and health over 
time following injury.  
Our findings suggest that spinal neuron downregulation of Akt 
phosphorylation correlates well with the time-course of apparent increase in 
PTEN activity as measured through the ratio of PTEN (active) to p-PTEN 
(inactive) (Fig. 17A & C). These results correspond to and confirm our previous 
hypotheses and findings, and support the use of Akt phosphorylation as a marker 
of PTEN activity. As such, our expectation that bpV(pic) was acting through 
PTEN was further confirmed by these results, as well as by the increase in 
phosphorylation of GSK3β, a downstream effector of Akt (Cross et al., 1995), 
following bpV treatment (Fig. 18B & C). This is in agreement with our prior finding 
that bpV(pic) increased phosphorylation of ribosomal protein S6, a marker for 
mTOR activity, in vivo.  
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The correlation of PTEN with elevated neuronal death was supported by 
the observed increase in caspase 3 activity 1d following SCI. Alternatively, 
bpV(pic)’s neuroprotective effects were reinforced by significantly reducing 
caspase 3 activity at this time point (Fig. 198 & C). Interestingly, the pattern of 
SCI-induced elevation in autophagosome formation (Kanno et al., 2009, Kanno 
et al., 2011, Walker et al., 2012, Zhang et al., 2013) and caspase 3 activity and, 
and bpV(pic)’s reduction in these activities is quite similar. Whether or not 
autophagy increase after SCI is neuroprotective (Sekiguchi et al., 2012), cannot 
be determined, however, this result supported bpV(pic) as a protective agent for 
neurons under traumatic conditions.  
To address this issue, a neuron scratch injury model previously used to 
replicate traumatic brain injury (TBI) in primary cortical neurons was augmented 
for use in this study (Zhao et al., 2012) and applied it to our established spinal 
neuron culture (Jiang et al., 2006). The results indicated bpV(pic) was protective 
in spinal neurons following traumatic scratch injury (Fig. 21B & C). The 
hypothesis was tested that traumatic injury in vitro would also affect PTEN and 
PI3K signaling resulting in a reduction in Akt phosphorylation and activity, and 
the results replicated our observations in vivo. An acute pattern of signaling 
changes was observed, and within 30 min post-scratch injury, spinal neurons 
significantly downregulated Akt activity (p < 0.05; Fig. 22A). Based on preliminary 
results, 30 min was selected as the time-point for further analysis.  
With a pre-treatment of 100 nM bpV(pic), Akt activity was significantly 
increased over the injury-only control (30’) and non-injured control (Fig. 21A, p < 
 
 
90 
 
0.05) suggesting bpV(pic) was acting through inhibition of PTEN, promoting PI3K 
activity and subsequent Akt phosphorylation. A similar result in Akt activity 
upregulation in vivo following SCI and bpV(pic) treatment was observed. In a 
prior in vivo study, ribosomal protein S6 activation by Akt, as measured through 
phosphorylation of S6 at ser 235/236, was also observed both in total tissue 
protein analysis and neuron immunofluorescence labeling. In addition to Akt 
activity upregulation, S6 phosphorylation and activation also increased following 
bpV(pic) treatment (Fig. 21B).  
Assessment of mTOR activity is often determined by observing or 
quantifying p-S6 (Park et al., 2008, Liu et al., 2010c, Sun et al., 2011, Walker et 
al., 2012). As such, bpV(pic) was proposed to act through this axis by 
disinhibiting PI3K and promoting downstream mTOR activity. Application of the 
PI3K inhibitor LY294002 significantly reduced the activity of Akt (Fig. 21A, p < 
0.001) as well as the phosphorylation of S6 (Fig. 21B, p < 0.01) following injury 
and bpV(pic) pre-treatment. The expectation was that trauma and bpV-mediated 
effects on mTOR activity would be diminished following PI3K inhibition if mTOR 
was regulated directly by PI3K signaling after injury. As both Akt and mTOR 
activities were greatly reduced after LY294002 application, despite bpV(pic) 
treatment, the results support the hypothesis concerning bpV(pic)’s mechanism 
of action through PTEN inhibition and activation of Akt/mTOR signaling axis 
following spinal neuron injury. This conclusion was further supported by the 
considerable downregulation of bpV(pic)-stimulated p-S6 increase through 
rapamycin treatment (Fig. 21B). This evidence is in line with our previous 
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findings, which suggested bpV upregulated mTOR activity and S6 
phosphorylation in penumbral neurons following SCI (Walker et al., 2012). 
Understanding cellular responses to insult is challenging, as intracellular 
protein interactions and activation of multiple signaling cascades complicate 
experimental interpretation. At the tissue level SCI causes disruption of axon 
tracts, immediate local cell death, and triggers delayed spread of damage and a 
glial response that chronically inhibits axonal regeneration. As demonstrated in 
the present study and related literature, bpV compounds have broad 
neuroprotective effects and result in preservation or recovery of a variety of 
functional abilities in animal models of neurological dysfunction. Quite recently, 
bpV compounds were shown to be protective or regenerative through p-Akt 
signaling in cortical neurons in ischemic injury models (Mao et al., 2013, Zhao et 
al., 2013). The present study’s findings support bpV-mediated neuroprotective 
effects observed in other injury models as well as our previous observations 
following SCI; however, this study is the first to demonstrate bpV effects on 
survival and PTEN/PI3K signaling in primary spinal neurons following traumatic 
injury. Also, these results show bpV(pic) stimulates mTOR activity, which 
suggests potential for not only neuroprotection but also regeneration (Park et al., 
2008, Liu et al., 2010c). Future studies will further dissect bpV’s mechanism of 
action on neuroprotection in spinal neurons, explore its effects on other cells 
such as glia, and examine its effects and mechanisms of action on neural repair 
and regrowth. 
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CHAPTER 4 
AIM 3 
INVESTIGATION OF POTENTIAL ADDITIVE OR SYNERGISTIC BENEFITS OF 
ACUTE BISPEROXOVANDIUM THERAPY COMBINED WITH SUBACUTE 
SCHWANN CELL TRANSPLANTATION POST-SCI 
 
Hypothesis: Administering a biphasic acute neuroprotective therapy (bpV) with 
subacute GFP-SC transplantation will promote more extensive neuroprotection 
and functional recovery, and improve the host-SC interaction over either 
treatment alone. 
 
Introduction 
Schwann cells (SCs) are integral and dynamic participants in peripheral nerve 
function and repair, and have been widely studied as a potential therapy for 
central nervous system (CNS) damage following injury. In spinal cord injury (SCI) 
research, SCs have been studied both directly and indirectly in various contexts 
ranging from peripheral nerve transplantation (David and Aguayo, 1981, David 
and Aguayo, 1985, Houle, 1991, Tom et al., 2009, Houle and Cote, 2013, Tom et 
al., 2013), SC-seeded channel engraftment (Xu et al., 1995a, Xu et al., 1995b, 
Xu et al., 1997, Xu et al., 1999, Iannotti et al., 2003, Deng et al., 2011, Deng et 
al., 2013) to cell suspension injection directly into or adjacent to the site of injury 
(Takami et al., 2002, Pearse et al., 2004b, Golden et al., 2007, Pearse et al., 
2007, Schaal et al., 2007, Siriphorn et al., 2010, Hu et al., 2013). Recently, many 
studies have investigated co-transplanting SCs with other cell types including 
olfactory ensheathing cells (OECs) (Pearse et al., 2007; Takami et al., 2002) and 
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glial restricted precursors (GRPs) (Hu et al., 2013). Hormonal therapy combined 
with SC transplantation has also been reported (Siriphorn et al., 2010). 
 The potential benefits provided by SCs in the injured spinal cord are many 
(Oudega & Xu, 2006); nonetheless, key limitations to SC transplantation as a 
single therapy for SCI persist. SCs die rapidly following transplantation into the 
lesion following contusion injury (Hill et al., 2007, Hill et al., 2006). It was reported 
that approximately 80% of transplanted cells die by necrosis and apoptosis by 
the end of the first week after transplantation (Hill et al., 2007). Although SCs can 
support considerable growth of propriospinal (Iannotti et al., 2004), reticulospinal 
(Schaal et al., 2007), raphaespinal (Novikova et al., 2008) and axons of other 
origin, these fibers fail to exit the graft into the caudal host tissue due to the 
inhibitory glial scar that encapsulates the contusive lesion. Delaying SC 
transplantation 7-10 days after injury avoids the cytotoxic nature of the acute 
injury site and allows for the formation of cystic cavitation in which to inject the 
cells (Hill et al., 2007, Hill et al., 2006, Martin et al., 1996). Adding a therapy that 
can reduce acute secondary injury prior to SC transplantation may benefit tissue 
sparing, repair of the injured cord, and potentially influence characteristics of the 
SC graft following transplantation. Combination therapies are necessary for 
advancing SC transplantation research and its potential as a viable clinical 
treatment for SCI (Bunge, 2008). 
 Approximately 60% of all human SCI occurs at the cervical level, yet there 
are strikingly few studies on SC transplantation following cervical SCI (Schaal et 
al., 2007, Novikova et al., 2008, Siriphorn et al., 2010). Therefore, a better 
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understanding of the effects and potential benefits of cervical SC transplantation 
and exploration of new therapeutic combinations in cervical SCI models are 
necessary. A pharmacological approach in combination with SC transplantation 
is practical from a clinical perspective due to the overall ease and rapidity of 
administration in acutely injured patients. In addition, autologous cell 
transplantation requires several weeks to isolate, purify, and expand a sufficient 
number of a patient’s own SCs for transplantation. A small-molecule targeting 
cell survival prior to SC transplantation may help curb secondary damage and 
promote a more robust spinal response to the delayed SC graft.  
 Bisperoxovanadium (bpV) compounds are dual protein-lipid phosphatases 
best known for their potent and specific inhibition of the phosphatase and tensin 
homolog deleted on chromosome ten (PTEN) (Schmid et al., 2004), an important 
regulator of cell survival and protein synthesis among other functions. PTEN 
antagonizes phosphatidylinositol-3-kinase (PI3K) activity, limiting downstream 
survival signaling through Akt and its effectors such as mTOR (Nave et al., 
1999), BAD (Datta et al., 1997), and glycogen synthase kinase 3β (GSK3β) 
(Cross et al., 1995). Neuroprotective and reparative effects of bpV compounds 
have been widely demonstrated in neurological disease and injury models (Mao 
et al., 2013, Song et al., 2010, Sury et al., 2011, Yang et al., 2007, Zhang et al., 
2007, Zhao et al., 2013) including SCI (Nakashima et al., 2008, Walker et al., 
2012).  
 Our studies showed that a member of the bpV family, bpV(pic), promoted 
significant long-term neuroprotection and functional recovery when given during 
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the first week following cervical hemicontusion SCI in rats (Walker et al., 2012). 
Combining acute bpV(pic) and sub-acute SC transplantation may have the 
potential to promote additional benefits by compensating for each individual 
method’s limitations and complementing each other’s strengths. To test this 
hypothesis, a systemic bpV(pic) treatment paradigm and transplanted green-
fluorescent protein (GFP) transgenic SCs for optimal histological identification 
were employed. Using a novel forelimb functional assessment and histological 
analyses, the results of this study shed light on the potential benefits and 
shortcomings of combining acute bpV(pic) treatment and sub-acute SC 
transplantation in a clinically-relevant cervical hemicontusive SCI model in rats. 
 
Materials and Methods 
 
Schwann cell culture 
Schwann cells (SCs) were purified and expanded as previously described 
(Morrissey et al., 1991, Xu et al., 1995b, Xu et al., 1999). SCs were harvested 
from the sciatic nerves of transgenic homozygote green fluorescent protein 
(GFP)-Rosa expressing adult female Sprague-Dawley (SD) rats (George Smith, 
Temple University), followed by purification and expansion in culture. The 
epineurium of the extracted nerves was removed, and sciatic nerves were 
minced into 2-3 mm long segments in cold Leibovitz L-15 medium (Gibco). These 
segments were transferred to 35 mm culture dishes (Nunc) containing DMEM + 
10% FBS (D10a). Approximately 8-12 segments were placed in one dish, and 3 
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dishes were prepared from one animal. Nerve segments were covered with just 
enough medium to prevent them from floating from the dish surface for future 
fibroblast migration. Medium was changed every 2-3 days, and each week, the 
segments were explanted into fresh 35 mm dishes with D10a medium to further 
promote fibroblast migration from the segments. When approximately all 
migrating cells were of SC morphology (bi- to tri-polar cells with long slender 
processes [~6 weeks]), the nerve explants were enzymatically digested in 
dispase/collagenase for 16 hrs, followed by wash in D10a medium and trituration 
through a sterile glass Pasteur pipette to obtain a single cell suspension. Once 
cells were ready, they were plated in poly-L-lysine coated 75 mm2 culture flasks 
(Nunc) in D10a medium plus the mitogens bovine pituitary extract (PEX) and 
forskolin to promote cell proliferation. The GFP-SCs were cultured to confluence 
with medium and mitogen change every 3 days. Cultures were > 98% pure SCs 
upon collection for transplantation (Xu et al., 1997, Xu et al., 1995b). Purified 
GFP-SCs at passage 3 or 4 were collected for transplantation into the spinal 
lesion cavity. 
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Figure 23. Experimental design for the bpV(pic)/GFP-SC combination study. 
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Animals and surgical procedures 
Adult female Sprague-Dawley rats (200-250 g, Harlan) (n = 33) were housed in 
an environmentally-controlled facility on a 12:12 light:dark cycle with ad libitum 
water and food access. The overall experimental design is illustrated in Figure 
23. Prior to surgery, animals were randomly assigned to five groups: 1) Sham or 
Naïve (n = 6), 2) Saline-treated only (Veh, n = 6), bpV(pic) treated (n = 6), 3) 
GFP-SC transplantation (n = 7), 5) bpV(pic) + GFP-SCs (n = 8). All animals in 
were used for both behavior as well as histological analysis after 10 weeks of 
testing. Results from these experiments were obtained from the animals stated 
here for each group. For surgical procedures, animals were anaesthetized 
intraperitoneally (IP) with a ketamine/xylazine cocktail ([87 mg/kg]/[12 mg/kg]), 
and received laminectomy only (sham operation) or unilateral cervical SCI 
performed as previously published (Walker et al., 2012). Briefly, the 5th cervical 
vertebra was stabilized with a customized device (Zhang et al., 2004) and a 
partial unilateral laminectomy was performed to expose the right side of the cord. 
A moderate unilateral injury was produced using the NYU/MASCIS Impactor 
(Gruner, 1992) (2.5 mm tip, 10g weight, 12.5 mm height) using previously 
published methods (Gensel et al., 2006, Walker et al., 2012). Sham animals 
underwent surgery but did not receive injury. All animals received subcutaneous 
injection of 5 mL 0.9% saline for hydration and were monitored for 24 hr in 
housing with controlled temperature. Animals were returned to the campus 
animal housing facility under veterinarian-guided observation and care upon 
recovery. A laboratory animal technician assisted in animal care. All procedures 
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and surgeries were approved under the Guide for the Care and Use of 
Laboratory Animals (National Research Council) and the Guidelines of the 
Indiana University School of Medicine Institutional Animal Care and Use 
Committee. 
 
Intraspinal GFP-SC transplantation 
Transplantation of GFP-SCs was slightly modified from previously published 
methods (Hu et al., 2013). Seven to eight days post-injury, GFP-SCs were 
harvested from culture flasks using 0.05% Trypsin-EDTA, washed and 
suspended in DMEM + 10% FBS on ice for cell transplantation. In preparation for 
transplantation, injured and sham rats were anesthetized using 
ketamine/xylazine and the surgical site was re-opened. Two groups of animals 
were designated to receive SC transplantation into the lesion cavity, SCs only 
and bpV + SCs. The spine was stabilized as described, and cell suspension (1 x 
106 GFP-SCs in 5μl medium) was stereotaxically injected into to lesion epicenter 
at a depth of 1.2 mm through a glass micropipette with an outer diameter of 50 -–
70 μm and beveled sharpened tip at a rate of ~1 μl/min. After injection, the 
pipette was left in place for 2 min to prevent cell leakage. Animals not receiving 
SC injection were surgically opened and the sham laminectomy or injury site 
exposed. Following surgery, animals were allowed to recover under conditions 
described above. 
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bpV(pic) administration 
Groups were randomly designated to receive intraperitoneal (IP) injections of 
bpV(pic) or 0.9% saline vehicle according to methods previously described 
(Walker et al., 2012). Briefly, 400μg/kg/day bpV(pic) (Enzo Life Sciences) was 
injected IP beginning immediately after injury, 2 hours post-injury, and twice daily 
for 7 days following SCI. Ultimately, two groups received bpV(pic) and the rest, 
including sham animals, received IP injections of saline according to the 
described treatment schedule. 
 
Behavioral testing  
For assessment of forelimb sensorimotor functional recovery, rats were provided 
flavored cereal rings in their home cage prior to and once per week for 11 weeks 
following injury (10 weeks after transplantation surgery) and tested as previously 
described (Walker et al., 2012) (Tables 2 and 3). Briefly, the rats were scored on 
a 0 to 8 point scale, with 8 being the maximal score, according to their ability to 
support, grasp, and manipulate treats with the injured and non-injured forelimb 
while eating the treats. Coordinated treat manipulation was defined as obvious 
consistent coordinated handling of the treat by both forelimbs during eating. 
Three trials (rings) were scored and the average score was presented for each 
rat during a testing session. The test was performed by 2 individuals blinded to 
the animals’ conditions. 
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Ventral horn neuron and lesion cavity quantification 
Twelve weeks post-injury (11 weeks post-transplantation), tissue was dissected 
and processed as previously described (Liu et al., 2006, Walker et al., 2012). In 
brief, a 1 cm segment of cervical cord including the injury epicenter was isolated, 
cryopreserved, and sectioned using a cryostat (Leica) at 20 μm thickness in the 
transverse or longitudinal horizontal planes on Superfrost Plus slides (Fisher 
Scientific). Tissue was kept at -20o C until utilized. Some tissue underwent cresyl 
violet acetate staining with eosin counterstaining (CVE). CVE staining was used 
to quantify the number of ventral horn neurons at and 2 mm rostral and caudal to 
the injury epicenter (Fig. 28). A horizontal line was drawn across the transverse 
section passing through the central canal to establish a standard anatomical 
region for quantifying neurons. All identifiable ipsilateral neurons in three 
adjacent sections ventral to this line in laminas VIII and IX, exhibiting dark, evenly 
distributed cresyl violet staining, were manually quantified using Neurolucida 
software (Microbrightfield, Inc). The average number of neurons counted for all 
three adjacent sections per animal at the three designated locations was 
obtained, and a group-mean neuron count was obtained. CVE stained tissue was 
also used to measure cavitation at the injury epicenter. Open cavities were 
traced using contour mapping in Neurolucida software to obtain cavity area. 
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Assessment of lesion and spared tissue 
Using CVE stained sections to identify the injury epicenter, adjacent sections 
were selected for immunolabeling of the glial scar interface. Adjacent sections 
were processed as previously described for immunofluorescence labeling. 
Briefly, tissues were blocked for non-specific binding of antibody and incubated 
overnight at 4o C with primary antibody against glial fibrillary acidic protein 
(GFAP), a marker of reactive astrocytes and the glial scar (1:200, Sigma). To use 
a clearly defined lesion border, GFAP immunolabeling demarcated the interior 
and exterior of the lesion by the labeling of the glial scar interface. This interface 
served as the boundaries of the lesion, and the area interior to this interface was 
assessed as a measure of lesion area at the epicenter. As the inverse of this 
value, spared tissue was calculated as all area of the ipsilateral cord outside the 
internal glial scar interface. 
 
Quantification of the GFP-SC graft 
To provide an estimation of the SC graft in relation to the lesion, both GFP-
labeling and CVE staining of transverse sections were used to identify the graft at 
the epicenter of injury which corresponded to region of the maximal cross-
sectional graft area. At the epicenter, SC grafts, if present, were traced using 
contour mapping in Neurolucida for each transplanted animal in the SCs group 
and bpV + SCs group. The average SC graft area per group was measured, and 
was presented as mean absolute graft area at the lesion epicenter. The total 
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area of the graft for each animal was also divided by the epicenter lesion area, 
which provided a % SC graft size of lesion area. 
 
Immunofluorescence labeling of axons, vasculature and macrophages  
Immunofluorescence double labeling was performed as previously described (Liu 
et al., 2006, Walker et al., 2012). In brief, animals were transcardially perfused 
with 4% paraformaldehyde in 0.1 M PBS following an overdose of 
ketamine/xylazine. A 1 cm spinal tissue segment including the epicenter (5 mm 
rostral and caudal) was dissected and removed, cryoprotected in 30% 
sucrose/PBS solution at 4o C, and sectioned on a cryostat at 20 μm thickness 
and mounted on Superfrost slides. Sections were prepared as described above 
and incubated with the following primary antibodies simultaneously with rabbit 
anti-GFAP (1:200): mouse anti-SMI-31, a marker for non-degenerated axons 
(1:1000; Chemicon), mouse anti-rat endothelial cell antigen-1 (RECA-1), a 
marker for rat vasculature (1:200) (ABD Serotec, Inc.), and mouse anti-ED1 
(1:200; Chemicon), a marker for macrophages. The next day, sections were 
incubated with rhodamine-, fluoroisothiocyanate-, or AMCA-conjugated goat anti-
rabbit or anti-mouse antibodies (1:100, Jackson ImmunoResearch Lab). 
Coverslips were mounted on the slides with Fluoromount G. Pre-immune serum 
was used as a control to confirm the specificity of the antibody. Images were 
obtained with an Olympus BX60 epifluorescent microscope and Neurolucida 
software (Microbrightfield, Inc.). 
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Statistical Analysis 
A two-tailed unpaired Student’s t-test was used to determine statistical 
significance between two groups. Statistical significance between multiple groups 
was determined using a one-way ANOVA with post-hoc analysis if significance 
was established. All statistics were calculated using GraphPad Prism 5.0 
software (GraphPad, Inc.), with a p value < 0.05 considered statistically 
significant. 
 
Results 
 
bpV alone and combined with SC transplantation improved forelimb 
function 
To test the recovery of forelimb function, a cereal ring treat-handling test was 
administered for 10 weeks post-transplantation surgery. Throughout testing, all 
groups performed dependably with an overall trend of improvement (Fig. 24). At 
Week 10, only animals in the bpV (p < 0.05) and bpV + SCs (p < 0.01) treatment 
groups scored significantly higher than saline-treated (Vehicle) control aniamls. 
The combination treatment group also scored significantly higher than animals 
treated only with SCs (p < 0.05). No statistical significance was observed for 
forelimb recovery scores between bpV and SCs, or bpV-only vs. bpV + SC 
treatment groups at the end of testing. 
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Figure 24. Forelimb sensorimotor assessment scores. Rats were tested on 
coordinated forelimb movement and manipulation of cereal rings during eating. 
At the end of the study bpV + SCs and bpV-only group scores were significantly 
higher than the Vehicle group. The combination bpV + SCs scores were also 
significantly higher than the SCs group at 10 weeks post-transplantation surgery. 
#, p < 0.05 vs. Veh; ## p < 0.01 vs. Veh; ### p < 0.001 vs. Veh; X, p < 0.05 vs. 
SCs group. 
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bpV and bpV + SCs significantly reduced lesion and cavitation, and 
increased spared tissue and ventral horn neurons  
As a measure of neuroprotection, lesion area, spared tissue, and cavity size 
were calculated. At the conclusion of the study, tissue from both bpV and bpV + 
SCs groups showed significantly reduced lesion area and increased spared 
tissue area (p < 0.01 & p < 0.05, respectively; Fig. 25C,E,F-G). The bpV 
treatment groups also showed significantly reduced lesion area and increased 
spared tissue over SCs only treatment (p < 0.05; Fig. 25F-G). Decreased lesion 
area highly correlated with improved functional assessment scores (R2 = 0.93) 
(Fig. 26). Lesion cavity area was significantly reduced in all treated animals (bpV 
and bpV + SCs, p < 0.01; SCs only, p < 0.05) compared to the Vehicle control 
animals (Fig. 27B,D,E), however, no significant difference was observed between 
the treatment groups. Similar to the trend observed for lesion and cavity 
reduction and overall tissue sparing, both bpV and bpV + SCs treatment groups 
promoted significant ventral horn neuron sparing compared to Vehicle treated 
animals (p < 0.05; Fig. 28A & B), though only 2.0 mm caudal to the injury 
epicenter. A similar trend was observed 2.0 mm rostral to the epicenter, but the 
quantification difference was not statistically significant. Almost no neurons were 
observed at the injury epicenter, therefore, no significant difference was 
observed between groups. 
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Figure 25. bpV and bpV + SCs reduced lesion and enhanced spared tissue. 
Method of tissue assessment (A). bpV (C, G & H) and bpV + SCs (E, G & H) 
significantly reduced lesion and enhanced spared tissue compared to Vehicle-
treated animals (B, G & H). Animals treated with SC transplant only (D, G & H) 
exhibited a trend in neuroprotective measures, but showed no statistical 
significance compared to the Vehicle group. *, p < 0.05. 
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Figure 26. Correlation between behavioral scores and lesion size. Increase 
in behavioral scores highly correlated with reduction in lesion size by group. 
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Figure 27. Assessment of lesion cavity following treatment. All treatment 
groups significantly reduced lesion cavitation versus Vehicle-treated rats (A – E), 
though not significantly between each other. *, p < 0.05; **, p < 0.01. 
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Figure 28. Ventral horn neuron quantification 2 mm rostral, caudal and at 
the epicenter of injury. Illustration of the region of quantification (A). Only bpV 
and bpV + SCs groups significantly increased ventral horn neuron count 2 mm 
caudal to the lesion (B). *, p < 0.05. 
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Maximal SC graft area between SC and bpV + SC groups 
After outlining and quantifying the SC graft area at the lesion epicenter for all 
animals, the results showed that total SC graft area is similar between SC only 
and the bpV + SCs treatment groups (Fig. 29C-E). However, as the lesion area 
affects and may be influenced by the graft, to best compare the graft size 
between both groups was to divide the cross-sectional area of the SC graft at the 
epicenter by the area of the lesion for that animal. This revealed a much different 
comparison, showing a greater graft-to-lesion ratio in the bpV + SCs group 
compared to SC transplantation only; however, this difference was not 
statistically significant. This finding is logical due to the decreased lesion 
observed in the combination group in comparison the SC transplantation only 
group. However, whether the SC transplantation enhanced lesion reduction or 
the lesion in which the graft was initially injected was smaller cannot be 
determined from these data. Nonetheless, functional assessment results suggest 
bpV may mediate significant neuroprotection and lesion reduction within the first 
week post-injury. Also, both bpV and bpV + SC groups show similar lesion 
reduction ability which suggests bpV may have already reduced the lesion cavity 
before SCs were transplanted, resulting in the observed trend in increased graft-
to-lesion ratio. 
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Figure 29. Calculation of GFP-SC graft area between SCs and bpV + SCs 
groups. Vehicle (A) and bpV (B) groups showed no GFP labeling in the lesion, 
while transplanted animals did (C & D), as expected. Overall GFP-SC area was 
similar between groups (E), while bpV + SCs exhibited greater GFP-SC/Lesion 
Area ratio than animals with SCs only although this difference was not 
statistically significant (F). 
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Axonal and vascular growth occurred in all SC grafts 
To first determine whether the GFP-SC grafts promoted ingrowth of host tissue, 
axons and vasculature were immunolabeled with antibodies against SMI-31 and 
RECA-1, respectively, and the center of the graft was examined. Animals not 
transplanted with SCs were also labeled and examined. As shown in Figure 30 
(A-D), non-transplanted rats exhibited little to no SMI-31+ axons within the 
boundaries of the GFAP scar. In contrast, SC transplantation only (Fig. 30E-H) 
and bpV + SCs (Fig. 30I-L) groups promoted remarkable axonal growth into the 
SC graft. Overall, axonal presence in the graft was similar between the two 
transplantation groups. 
 Likewise, vascular presence in the lesion was minimal in non-transplanted 
animals (Fig. 31A & B), but evident within the lesion/graft epicenter for the SC 
only (Fig. 31C & D) and bpV + SCs groups (Fig. 31E & F). Like axonal presence 
in the graft, vasculature was similar between the two SC-transplanted groups 
through general observation. 
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Figure 30. GFP-SC transplantation promoted extensive axon growth into 
the lesion. Few to no SMI-31+ axons were observed within the lesion in animals 
with no SC graft (A – D). Animals treated with GFP-SC transplantation (E – H) or 
bpV + GFP-SC transplantation (I – J) showed considerable SMI-31+ axon growth 
in the SC graft and lesion. Growth was similar between the two transplantation 
groups. 
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Figure 31. SCs promoted vascular growth into the graft. Like axons, the 
GFP-SC graft was favorable for RECA-1+ vascular growth (white arrowheads) (C 
– F), while animals without a graft showed fragments or no vasculature inside the 
lesion (inset) (A – B). 
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Macrophage response to SC transplants 
As determined through ED1-immunolabeling, macrophages responded to the 
injury in all groups (Fig. 32A-D); however, macrophages were most abundant in 
and around the SC graft in both SCs only and bpV + SCs groups (Fig. 32C & D). 
In non-transplanted animals (Veh and bpV groups, Fig. 32A & B), ED1+ 
macrophages were more dispersed outside the lesion with a few individual cells 
or random aggregations of macrophages observed within the GFAP boundaries 
of the lesion (Fig. 32A & B, white arrowheads). With SCs present inside the 
lesion, macrophage aggregations were much more common, although mostly 
limited to the periphery of the graft (Fig. 32C & D, white arrowheads) in both SC-
transplanted groups. 
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Figure 32. Transplantation of SCs enhanced macrophage presence within 
the lesion. In vehicle (A) and bpV (B) groups, few ED1+ macrophages (red) 
(marked by white arrowheads) were typically seen within the lesion, though many 
were observed outside the lesion cavity primarily within or adjacent the GFAP+ 
glial scar (blue). In SC (C) and bpV + SC (D) groups, a large macrophage 
presence was observed inside the lesion and the SC graft (green). Aggregations 
of macrophages were also common within the glial scar (pink), suggesting a 
chronic host tissue reaction to the exogenous GFP-SCs at 10 weeks post-
transplantation. 
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Discussion 
The results of this study show bpV promotes neuroprotection and functional 
recovery, and that these benefits are similar to those provided by the 
combination bpV + SCs treatment. This evidence supports bpV as the primary 
neuroprotective component in the combined treatment group. Also, the data 
confirm bpV as a valuable therapy for improving functional recovery which is 
likely closely tied to its neuroprotective effects. When transplanted alone, SCs did 
not significantly improve forelimb functional ability at the end of the study (Fig. 
24). They did, however, significantly improve functional recovery until week 4 
post-transplantation when forelimb ability began to decline sharply until week 6. 
From weeks 6 through 10, behavioral scoring was stable, but not statistically 
significant over saline-treated animals (Fig. 24). The early increase in functional 
ability suggests the cells may have been contributing to neuroprotection or repair, 
resulting in significantly improved functional recovery. The downturn in scoring 
observed at 5 weeks post-transplantation suggested the graft may have been 
negatively affected by an immune response of the host tissue leading to 
disruption of functional ability. However, when the maximal graft area at the 
epicenter was calculated, total area between SCs only and bpV-SCs groups was 
almost identical (1.88 x 105 +/- 6.3 x 104 vs. 1.87 x 105 +/- 5.4 x 104 µm2; Fig. 
29E), and the ED1+ macrophage response to the SC graft between these two 
groups was also similar, suggesting some other phenomenon potentially 
instigated the functional decline observed mid-study.  
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 Although SCs remained present in most transplanted animals in both SCs 
and bpV + SCs groups throughout the study, the behavior of the SCs may have 
been altered in some way although no clear effects were observed that could 
explain the functional reduction. Treatment with bpV, regardless of subsequent 
SC transplantation, promoted greater functional recovery over SCs alone. Even 
still, there was no distinct evidence or observation that bpV directly affected the 
SC graft or that it influenced host tissue interaction with the transplanted SCs. As 
such, the SCs were likely of value in combination with bpV in promoting subacute 
tissue growth following bpV-mediated acute neuroprotection, and these benefits 
marginally affected functional recovery. Further analysis of vascular growth in the 
graft would help identify whether these vessels were functional, and whether their 
effects may be beneficial or detrimental to the grafted cells or surrounding host 
tissue. Evidence suggests angiogenesis is beneficial following SCI (Han et al., 
2010), and can promote axonal sprouting and growth (Loy et al., 2001, Dray et 
al., 2009), all findings that support the results observed in the present study. 
 As seen for functional recovery, bpV and the bpV + SCs combination 
groups showed similar lesion area reduction and increased spared tissue 
compared to SCs only and Vehicle-treated rats (Fig. 25B-G). Animals that 
received only SC transplantation did not exhibit such significant neuroprotection 
compared to the Vehicle group (Fig. 25B,G-H). In addition, average behavioral 
assessment scores correlated well with lesion area as a percentage of ipsilateral 
cord area (Fig. 26) further emphasizing the benefits of bpV treatment and 
highlighting the sensitivity of the functional assessment. 
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 We previously demonstrated direct effects of bpV treatment on lesion and 
cavitation reduction, and overall tissue and neuron sparing in a cervical 
hemicontusion model (Walker et al., 2012), and the data from the current study 
are comparable. The advantageous effects of bpV(pic) are further demonstrated 
through the functional and histological analyses of the bpV + SCs group, as the 
outcomes closely resemble those for the animals treated only with bpV. This 
suggests that bpV treatment during the first week post-SCI likely promotes most, 
if not all of the neuroprotection and related recovery as measured in this and 
previous studies. The functional benefits of SCs have been reported, however, 
their effect has not been consistent.  
 In one of the few cervical injury SC transplantation studies, SC 
transplantation improved forelimb hang time and grip strength (Schaal et al., 
2007). In other studies on thoracic contusive SCI, SCs have demonstrated the 
ability to enhance Basso, Beattie, and Bresnahan (BBB) (Basso et al., 1995) 
hindlimb locomotor scores (Takami et al., 2002, Barakat et al., 2005). Contrary to 
these results, Pearse and colleagues showed no benefit in BBB scoring for 
animals transplanted only with SCs over contusion injury alone, although they 
demonstrated that SCs could significantly improve hindpaw rotation in footprint 
analysis (Pearse et al., 2004a, Pearse et al., 2007). It has been demonstrated 
that SCs are more effective for repair than other cell types for transplantation, 
such as olfactory ensheathing cells or glia (OECs or OEGs) for treating 
experimental contusive SCI (Takami et al., 2002); however, in most studies, 
combining SCs with other therapies or genetically-modifying SCs promotes more 
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notable recovery in rat behavioral assessments than SCs alone even when SCs 
exhibit a benefit. In one recent study, injured animals grafted with SCs genetically 
modified to overexpress the neurotrophic factor GDNF showed improved 
locomotor recovery over SCs alone (Deng et al., 2013). These mixed results 
suggest that although SCs promote positive results as a therapy for SCI, their 
effects overall may not be substantial for recovery unless other therapies are 
involved. Our findings in the current study support this hypothesis. 
 Based on functional assessment results, bpV’s dramatic effect on function 
recovery is maintained over the course of both 6 (Walker et al., 2012) and 11 
weeks post-SCI. Further affirming these results, the combination therapy showed 
very similar neuroprotective effects, as well as sustained improvement in 
functional outcome over the course of this study. The functional assessment 
score for the combination group was higher than all individual treatment groups 
at the end of the study, but only significantly increased over SCs only and 
Vehicle-treated animals. From these observations, bpV and SC transplantation 
may not act synergistically, but rather additively through separate mechanisms 
based on their period of treatment and influence on host tissue. The true 
relationship, if any, between these two treatments in contributing to functional 
recovery is not fully clear from the results of this study. Nevertheless, our findings 
suggest bpV may have played a more important role in neuroprotection and 
functional recovery than SC transplantation. Also, both bpV and bpV + SC 
groups showed similar lesion reduction ability which raises the possibility that 
bpV may have already reduced the lesion before SCs were transplanted. Despite 
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not having cells transplanted into the lesion, bpV exhibited similar lesion cavity 
reduction to both the SCs and bpV + SCs treatment groups, further supporting 
this interpretation. 
 In continuation of the beneficial influence of bpV on neuroprotection, only 
bpV and bpV + SCs groups showed significant ventral horn neuron sparing 
caudal to the injury, and a similar trend rostrally (Fig. 28B). In our previous study, 
comparable effects on ventral horn neuron sparing were observed following bpV 
treatment. Both bpV and bpV + SCs exhibited similar effects in this outcome 
measure, which further supports bpV’s neuroprotective effects over SC 
transplantation. Although the total area of the SC graft at the epicenter was 
similar between groups, the graft-to-lesion ratio was higher in the combination 
group compared to animals that received only SC transplantation (Fig. 29F). This 
result is reasonable, as the lesion was greatly reduced in the combination group 
compared to SCs-only group. 
 The potential value of SC transplantation was observed in examination of 
host tissue growth into the graft, and thus, into the lesion area. The amount of 
SMI-31+ axons observed in the SC graft was similar between SCs and bpV + 
SCs groups (Fig. 30E-L); however, the axon-to-lesion area ratio was likely higher 
due to the reduced lesion in the combination therapy group (data not shown). 
When investigating axonal presence within the lesion in non-grafted animals (Fig. 
30A-D, a bpV treated animal), almost no axons were observed inside the GFAP 
boundaries of the lesion. This same pattern was observed for RECA-1+ 
vasculature. In both transplant groups, SCs exhibited clear vascular growth at the 
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epicenter of the graft (Fig. 31C-F), while negligible vasculature was observed in 
the lesions of non-SC transplanted animals (Fig. 31A & B). To our knowledge, 
this is the first study to observe vascular growth into the SC graft in a cervical 
SCI model. The exact mechanism influencing vascular generation in this model is 
unclear. 
 What potentially contributed to the functional ability increase in the bpV 
and bpV + SCs groups based on our histological findings? One explanation 
centers on the spared neurons observed rostral and caudal to the injury 
epicenter. By sparing ventral horn neuron in laminas VIII and IX, more efferent 
motor activity could be provided to the musculature of the forelimb. Since the 
most significant increase was observed at the caudal end of the lesion, this 
correlates to neurons involved in more distal forelimb function (near C7) which 
associates to a large motor neuron population innervating the triceps brachii 
muscles, the major extensor muscle group of the forelimb (Tosolini and Morris, 
2012). This could result in more joint extension and range of motion, and thus, 
better ability to coordinate sensorimotor activity of the forelimbs while eating 
cereal rings. We previously observed close correlation of our forelimb scoring 
scale with joint articulation ability and the C5 hemicontusion injury produced in 
this study results in a chronically flexed forelimb and forepaw; therefore, our 
histological findings plausibly support the functional outcome observed in this 
assessment.  
As both of these groups exhibited significantly reduced lesion areas and 
increased overall spared tissue at the lesion epicenter, a measure that 
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significantly correlates with lesion severity and behavioral analysis following 
contusive SCI (Noble and Wrathall, 1985, Bresnahan et al., 1987), the increase 
in functional ability could also have resulted from sparing of both gray and white 
matter in these two groups. However, as all injured animals failed to fully extend 
and grasp the treats with the digits suggests chronic corticospinal tract damage 
in the ipsilateral dorsal column. Therefore, further analysis of bpV’s effects on 
this tract could help shed light on mechanisms to target CST protection and 
repair to further improve the rats’ ability to handle the cereal treats with the 
forepaws during the treat manipulation exercise. 
 Remarkably, few other studies have been reported on SC transplantation 
at the cervical level, however, those that were performed focused on combining 
SCs with an additional treatment or strategy to produce host and SC graft effects. 
As previously discussed, Schaal and colleagues transplanted SCs into the 
contused cervical spinal cord and observed surpaspinal axonal growth into the 
graft, as well as SC-mediated forelimb functional recovery (Schaal et al., 2007). 
Though we did not see such significant recovery from only SC transplantation in 
our study, our behavioral assessment was designed to look at fine forelimb 
sensorimotor coordination in a hemicontusion model. Schaal’s study utilized 
more forepaw strength-based assessments following a bilateral injury. We did 
see axonal growth into the graft, although our study did not assess the origin of 
these axons. In 2008, one group loaded SCs into poly-β-hydroxybutyrate (PBH) 
channels, implanted the graft into the hemisected gap, and identified 
serotonergic raphespinal and CGRP fibers, but not descending motor rubrospinal 
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axons within the graft (Novikova et al., 2008). The PBH channels did not promote 
axonal growth when implanted alone, suggesting this material played a limited 
role in the growth seen with in combination with seeded SCs. However, no other 
characteristics, such as functional recovery or neuroprotection, were investigated 
to gauge the influence or importance of SCs and the promoted axonal growth 
observed in the study. 
 The most comparable study of the cervical SC transplantation studies 
investigated a co-treatment of 17β-estradiol with transplantation of SCs into the 
hemicontused cervical spinal cord (Siriphorn et al., 2010). In this study, a 17β-
estradiol (E2) pellet (5 mg/pellet, 21-day continuous release) was implanted 
subcutaneously 30 min following injury. After a delay of 8 days post-SCI, 5-(and-
6)-carboxyfluorecein diacetate succinimidyl ester (CFSE)-labeled SCs were 
transplanted into the contusion site and animals were allowed to survive for 7 
days following transplantation. Though this study is relevant and yielded novel 
information, there were notable differences than the study presented here. First, 
the authors’ primary goal was to determine whether E2 could protect 
transplanted SCs and promote their survival following transplantation. The 
authors also employed in vitro analyses to identify mechanisms as to how E2 
could be protective to SCs, however, no in vivo effects of the drug on pre- or 
post-transplantation tissue morphology or cellular sparing were examined, 
minimizing our understanding of the impact on host tissue over direct effects on  
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the cells post-transplantation. Furthermore, the combined E2/SC transplantation 
treatment intentionally overlapped to investigate one treatment’s effect on the 
other.  
Our goals were different by comparison, as we designed our study to 
provide a non-overlapping two-phase treatment regimen, although we cannot 
discount the possibility some minor overlap occurred at the transition between 
bpV(pic) treatment and SC transplantation. Current studies are investigating 
potential effects of bpV on SCs in vitro to address this possibility, as well as to 
investigate other potential combination benefits of bpV and SCs for SCI. As acute 
sustained E2 delivery can protect SCs under deleterious conditions in vitro and in 
vivo, experimentation with neuroprotective bpV therapy with E2 could be useful 
to help identify promising combination therapies to augment the effects of SC 
transplantation following SCI. 
 In summary, three main conclusions can be made from the results of the 
present study concerning bpV combination therapy with SC transplantation, and 
SC transplantation in general: 1) Biphasic combination therapy, with bpV 
targeting acute secondary damage combined with delayed SC transplantation, 
can impart separate yet potentially additive benefits resulting in neuroprotection 
and enhanced functional recovery, 2) SCs alone appeared to play a limited role 
in functional recovery, and 3) transplanted SCs exhibit long-term survival in the 
contused cervical spinal cord, regardless of whether or not a co-therapy is 
added. Separate from the combinatory treatment aspect of the study, our results 
affirm bpV as a potent therapeutic that can significantly reduce lesion and cavity 
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formation, as well as promote functional recovery when given systemically 
following clinically relevant experimental SCI.   
 Ultimately, the results of this study suggest bpV promoted most of the 
neuroprotective benefits, and played a larger role in functional recovery than SC 
transplantation when the two therapies were combined. Transplanted SCs 
elicited a dynamic host tissue response, promoting considerable axonal and 
vascular ingrowth over the course of the study. The impact of these responses 
on recovery, however, is indeterminable from the observed results. The 
vasculature observed in the graft, if functional, could have provided nutrients and 
growth components necessary for long-term SC survival and axon growth. 
Without a treatment to dissolve the glial scar formation at the caudal end of the 
lesion, it is unlikely any axons that entered the graft were able to exit and make 
functional connections in the host tissue. This could explain the limited effects SC 
transplantation alone had on functional recovery in this study. As such, the bpV 
component of our combination therapy possibly enhanced recovery through 
acute sparing of neurons and other cells from secondary damage following SCI. 
If combined with another therapy to degrade the glial scar or allow SC 
overexpression of trophic factors, transplantation of SCs may contribute more 
substantially to neuroprotection, axonal growth into caudal host tissue, and 
forelimb functional recovery. Future studies will address these and other issues 
concerning the potential of SCs in combination therapies following SCI. 
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CHAPTER 5 
CONCLUSIONS 
 
Although this work highlights research directed toward improving repair and 
recovery following SCI, this and all CNS injuries cause a syndrome of physical 
and functional effects that is seemingly insurmountable from the present point of 
view. Nonetheless, the progression of work in the field, including the contribution 
made in the present volume, illustrates the headstrong optimism that many small 
hits over time can crumble the wall separating us from a cure for CNS injury and 
resulting functional dysregulation and paralysis. In many ways, the preceding 
chapters highlight important aims of focus and potential achievable outcomes 
that are possible in targeting these areas. 
 The molecular events that unfold following SCI have long been of 
research interest; however, the outcome emphasis and interpretation has many 
facets as intracellular dynamics of signal pathway networking is extremely 
complex. The dissection of PTEN/PI3K/Akt signaling following SCI helped build 
on previous studies (Yu et al., 2005, Kanno et al., 2009, Kanno et al., 2011) by 
adding extra information and histological interpretation of the cellular expression 
of key molecules in the pathway in the acute period post-SCI. Importantly, our 
work used a clinically-relevant cervical hemicontusion model, versus thoracic 
injury, which may present different cellular injury responses. In addition, we 
added bpV as a tool to inhibit PTEN and examine the neuroprotective and 
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functional recovery effects to better illustrate the role of this signaling pathway 
following SCI.  
 Cervical SCI damages descending supraspinal axon tracts originating 
from neuron populations in the brain, among ascending sensory fibers and other 
spinal structures and cells located in the region of injury. Being that the cervical 
cord is located close to the brain in comparison to the thoracic cord, damage to 
tracts in this region impart more pathological changes and cell loss in the cell 
bodies of originating neurons than damage inflicted more caudally (Egan et al., 
1977). Likewise, axotomy of brainstem rubrospinal axons, which impart 
descending flexor-biased motor regulation induce further neuron degeneration 
and death in the red nucleus than cervical SCI (Liu et al., 2003). This variation in 
the influence of injury on supraspinal neurons based upon distance of insult from 
the cell body adds another dimension to understanding both the more common 
cervical SCI in the human population, as well as the effects of cervical injury and 
treatments in animal models on supraspinal neuron nuclei of origin and their 
spared or damaged axonal projections in the region of injury in the spinal cord. 
 If cervical SCI is the most frequently diagnosed form of SCI in humans, 
and the potential spinal and supraspinal influences of injury are different than 
those of the more commonly used experimental thoracic SCI models, then more 
use and investigation of cervical SCI models will likely yield more readily 
translatable information from bench to bedside in developing treatments for 
human SCI. This difference in pathological progression based upon region of 
injury in the spinal cord also highlights important considerations of treatment 
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effects in different SCI models used in neurotrauma research. One example 
concerns potentially different variables affected by bpV(pic) treatment in cervical 
and thoracic SCI. Nakashima et al. (2008) demonstrated bpV(phen), a related 
PTEN inhibitor, was neuroprotective following thoracic injury, an effect we also 
observed in cervical SCI. It would be interesting, however, to determine the 
supraspinal effects of SCI between these two regions as any potential 
differences between the two could have important implications on the potential 
for promotion of axonal tract sprouting and regeneration by bpV compounds.  
 If the brainstem or cortical population of neurons are healthier and exhibit 
less degeneration following thoracic versus cervical SCI, then a more robust 
sprouting or regrowth effect may be observed following bpV treatment due to the 
ability of bpV PTEN phosphatase inhibition (Mao et al., 2013) and PTEN deletion 
or expression inhibition (Park et al., 2008, Liu et al., 2010) to promote neuronal 
regeneration. Investigation of regenerative effects of bpV(pic) was not a focus of 
the studies presented here, however, future studies have been designed to 
explore potential regenerative effects of bpV compounds on axon regeneration 
following SCI.  
 Given that major tracts of the spinal cord, for example the corticospinal 
tract, are represented quite differently anatomically such that the injury produced 
in the studies described here will damage different sensorimotor axonal tracts in 
humans, consideration must be taken when extrapolating such experimental 
information to the human condition. Nonetheless, the cervical hemicontusion 
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model is one of the closest models characterized to experimentally produce 
relevant replication of anatomical cervical SCI in humans. 
 Concerning the use of pharmacological agent, bpV(pic) in the present 
studies, it was highly important to 1) determine whether spinal neurons were a 
likely target of the effects of the drug in vivo, 2) investigate a time-course 
response of this pathway in neurons following SCI to assess the acute recovery 
pattern of Akt signaling, and 3) compare and analyze the drug’s protective and 
molecular signaling effects in isolated spinal neurons in vitro to compare verify 
the effects witnessed in vivo. In the end, our findings contribute knowledge on the 
neuronal effects of bpV treatment, and thus, PTEN inhibition in spinal neurons. 
Results obtained from the initial bpV treatment study were validated to some 
extent by the results of the in vitro experiments. Nevertheless, other cellular 
effects such as the influence of bpV on astrocytes and oligodendrocytes were not 
considered for these studies but this does not diminish the importance of such 
investigation. The effects of PTEN inhibition lend itself to potential acceleration of 
astrogliosis (Cai et al., 2001, Codellupi et al., 2009) as well as regulation of 
myelination integrity by oligodendrocytes (Harrington et al., 2010). If astrogliosis 
was influenced by bpV treatment in the present research, it did not significantly 
prohibit neuroprotection and functional recovery provided by the drug. The drug 
may have actually promoted benefits of astrocyte activity during the acute phase 
following SCI. 
 The roles of astrocytes following SCI are intricate and important; however, 
they is mostly viewed in a negative light due to the well-known axon growth 
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inhibitory glial scar that forms over time after injury. Shortly after injury, however, 
astrocytes contribute considerably to local and regional protective and reparative 
events spanning from clean-up activities and re-establishment of a barrier 
between the spinal cord and the exterior environment. Various protective roles of 
reactive astrocytes include taking up excess excitotoxic glutamate, providing 
protection from oxidative agents, repair of the blood-brain-barrier in damaged 
tissue, and reducing inflammation and oxidative damage through sealing the 
lesion area via astrogliotic scar formation (Rothstein et al., 1996, Bush et al., 
1999, Chen et al., 2001, Faulkner et al., 2004, Hamby and Sofroniew, 2010, 
Sarafian et al., 2010). Given this list of positive functions of reactive astrocytes, 
and that PTEN downregulation and mTOR activity upregulation are suggested to 
play important roles the the reactive response of astrocytes, part of the 
neuroprtective effects of bpV(pic) treatment during the acute period following SCI 
may potentially be mediated by astrocytes. At present, however, the full influence 
of bpV(pic) on astrocytes cannot be fully determined. 
 The necessity of combination therapies with SC transplantation is quite 
clear, despite their benefits alone. The acute administration of bpV followed by 
subacute SC transplantation performed as described in Chapter 4 is the first 
biphasic study of its kind in cervical SCI research. The only other comparable 
study involved acute subcutaneous transplantation of a slow-releasing 17β-
estradiol tablet just after cervical hemicontusion, followed by a subacute SC 
transplantation (Siriphorn et al., 2010). One important difference between these 
studies is that the 17β-estradiol treatment released over 21 days, which was 14 
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days after SCs had been implanted. Also, the study primarily focused on this 
treatment’s effects on SC survival. Our focus here was to attempt to promote an 
acute prevention of secondary damage expansion with acute bpV therapy 
followed by a non-overlapping SC transplantation to encourage host-graft 
responses in the subacute to chronic periods following SCI. Our findings suggest 
that this two phase treatment paradigm can work to produce additive anatomical 
and functional effects over individual treatments alone. 
 One issue that deserves discussion is the contrast between the 
neuroprotective outcomes and the functional recovery differences of the 
treatment groups in the bpV-GFP-SC combination study. Neuroprotective effects 
and functional recovery was most significant in the bpV and bpV and GFP-SC 
transplantation combination treatment groups, while SC transplantation alone did 
not significantly influence these outcomes over non-treated injured animals (Figs 
24-28). Despite these results, two potential external factors could hamper the 
interpretation of the benefits, or lack thereof, concerning the treatments in this 
study: the severity of injury and the sensitivity of the outcome measures. 
 It has long been shown that contusion injury severity produced by the 
NYU/MASCIS impactor correlates well with degree of resulting physical and 
functional deficits (Basso et al., 1996). The injury produced in this study, a 10g 
weighted rod drop from 12.5 mm high onto the exposed spinal cord produces a 
comparatively moderate contusion injury within the parameters available in the 
impactor design (12.5 mm, 25 mm drop height etc.). This severity designation, 
however, is based upon measures of tissue and function from animals not 
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treated via SC transplantation. Also, though other studies have used SC 
transplantation in 12.5 mm weight drop injuries produced by the NYU/MASCIS 
impactor, these are mostly performed at the midline thoracic spinal cord (Takami 
et al., 2002, Pearse et al., 2004a, Pearse et al., 2004b, Hill et al., 2006, Golden 
et al., 2007, Hill et al., 2007, Pearse et al., 2007). Nearly all these studies contain 
some component of axonal growth analysis, yet only a few describe tissue 
sparing and neuroprotective effects of SC transplantation among other 
treatments.  
 Schaal et al. (2007) performed the only study involving transplantation and 
subsequent assessment of neuroprotection in a cervical contusion model. 
However, this study utilized a different impactor system to perform a more 
precarious midline cervical contusion rather than a hemicontusion. Still, SCs 
were shown to promote neuroprotective tissue sparing in addition to functional 
recovery in their study. This introduces the possibility that severity of the injury 
may contribute to the sensitivity to detect SC-mediated neuroprotective effects. 
Although the 12.5 mm drop height is considered to produce a moderate injury in 
the cervical hemi-contusion model utilized in the present studies (Gensel et al., 
2006), the current evidence is inconclusive as to whether this injury is severe 
enough to reveal clear neuroprotective lesion reduction and tissue sparing by SC 
transplantation alone.  
 This possibility is bolstered by the close functional outcomes between all 
treatment groups. The administration of bpV and SC transplantation as individual 
therapies were not significantly different, despite the statistical significance 
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between of bpV, but not SCs, over the scores of vehicle-treated animals. The 
combination therapy was significantly different than both vehicle and SC-only 
treated groups. Together these results suggest that bpV was more effective than 
SCs at promoting neuroprotection and functional recovery. When looking at the 
difference in scores however, bpV + SC treated animals scored only an average 
of two points higher on the forelimb assessment scale, with bpV-only treatment 
falling in between. These observations, in addition to those from the histological 
assessments suggest that the results may have been affected by a lack of 
sensitivity of the injury model or functional assessment, or both. Therefore, 
though the data support the conclusions about the benefits of bpV and the 
combination therapy following SCI, alternative influences or explanations for the 
results cannot be ruled out. 
 In summary, though the wall still stands between SCI and a cure, it is with 
hope that the work provided in this thesis helped, if ever so slightly, our efforts 
towards reaching that goal. Ultimately, the real merit of this work was the 
validation of the positive and overall effects bpV therapy and highlighting the 
benefits and limitations of combining bpV and SC transplantation following SCI. 
We also demonstrated that SCs can survive well into the third month post-
transplantation without immunosuppressant, which counters the previous findings 
of near total SC loss shortly after transplantation. Though the acute death and 
long-term survival were not of prime interest in the present study, the ability for 
the cells to promote extensive axon and vascular growth into the graft suggests 
that whatever SCs survive can interact remarkably well with host tissue over long 
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periods of time. The use of a cervical hemicontusion SCI model increased the 
clinical relevance of the research, and in the end, any work towards the goal of 
treating and someday curing SCI and other CNS injuries is of great value. 
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